[
  {
    "objectID": "talks/rstats_20240613_teaching/index.html",
    "href": "talks/rstats_20240613_teaching/index.html",
    "title": "A one year recap on teaching statistcis to medical students: how can R and Quarto help?",
    "section": "",
    "text": "Time and place: June 13 2024. Online\nSlides for this talk can be accessed here."
  },
  {
    "objectID": "talks/rstats_20240613_teaching/index.html#about-the-topic",
    "href": "talks/rstats_20240613_teaching/index.html#about-the-topic",
    "title": "A one year recap on teaching statistcis to medical students: how can R and Quarto help?",
    "section": "About the topic",
    "text": "About the topic\nThe Department of Biostatistics at University of Oslo offer statistics courses at different levels for medical students and PhD candidates with clinical backgrounds. The courses were traditionally taught with a focus on theory instead of data analysis, where SPSS and STATA were the tools of choice.\nSince 2023 spring semester, we have been gradually transforming some of our statistics courses into R, using Quarto course websites and Carpentries style live-coding instruction. With new Quarto tools (such as WebR) we also added interactivity in the code blocks. So far we have transformed two courses with over 100 students who have almost no programming experience. We have observed impressive progress in the skill development, and received significantly more positive feedback when it comes to statistics education.\nIn this talk, I would like to share our experience on the successes and challenges throughout the process. Looking back, is it cost-effective? Definitely. Can we do better in the future? Almost surely. If you are also planning to adopt new technology in your teaching activities, join us to learn more about what you can do to make the transition happen!\nCourse website can be accessed here"
  },
  {
    "objectID": "talks/rstats_20190402_blogdown/index.html",
    "href": "talks/rstats_20190402_blogdown/index.html",
    "title": "Building Website in R: Step by Step Introduction to blogdown",
    "section": "",
    "text": "Since this post doesn’t specify an explicit image, the first image in the post will be used in the listing page of posts."
  },
  {
    "objectID": "talks/ph_20220616_splverse/index.html",
    "href": "talks/ph_20220616_splverse/index.html",
    "title": "Sykdomspulsen: An automated public health surveillance platform",
    "section": "",
    "text": "About the talk\nWatch the talk on YouTube\nSykdomspulsen is a real-time analysis and disease surveillance system designed at developed at the Norwegian Institute of Public Health (FHI). Sykdomspulsen processes new data collected from 15 data sources (e.g., covid-19 cases), runs 1000.000+ statistical analysis automatically for all locations (nation, county, municipality) in Norway, produces 1000+ reports and alerts for public health authorities and shares data to the public on GitHub.\nSykdomspulsen runs on a collection of R packages, the {splverse}. {splverse} is an ecosystem for infectious disease surveillance, from analysis planning, statistical analysis to reporting via visualization, shiny website and Rmarkdown generated reports. In this talk, Chi will present how Sykdomspulsen does public health real-time surveillance during the pandemic using R. Chi will introduce some of the core packages and illustrate how they work together, with an example using real surveillance data published daily on GitHub.\n\n\nAbout the speaker\nChi is currently working at the Sykdomspulsen team as a researcher and R developer, at the Norwegian Institute of Public Health. Before she joined Sykdomspulsen in the middle of the pandemic (2020), she was a PhD student at the Department of Biostatistics at University of Oslo (OCBE), working on hospital EHR data."
  },
  {
    "objectID": "talks/ehr_20221013_ml_icu/index.html",
    "href": "talks/ehr_20221013_ml_icu/index.html",
    "title": "Machine Learning in Intensive Care Units",
    "section": "",
    "text": "A 45 minutes trial lecture to fulfill the requirement of my PhD degree."
  },
  {
    "objectID": "talks/community_20240710_camis/index.html",
    "href": "talks/community_20240710_camis/index.html",
    "title": "CAMIS: An Open-Source, Community endeavour for Comparing Analysis Method Implementations",
    "section": "",
    "text": "2024.7.8-11, Salzburg, Austria. Conference link: UseR!\nStatisticians using multiple softwares (SAS, R, Python) will have found differences in analysis results that warrant further justification. Whilst some industries may accept results not being the same as long as they are “close”, the highly regulated pharmaceutical industry would require an identical match in results. Yet, discrepancies might still occur, and knowing the reasons (different methods, options, algorithms etc) is critical to the modern statistician and subsequent regulatory submissions.\nIn this talk I will introduce CAMIS: Comparing Analysis Method Implementations in Software. https://psiaims.github.io/CAMIS/ It is a joint-project between PHUSE, the R Validation Hub, PSI AIMS, R consortium and openstatsware. The aim of CAMIS is to investigate and document differences and similarities between different statistical softwares such as SAS and R. We use Quarto and Github to document methods, algorithms and comparisons between softwares through small case studies, and all articles are contributed by the community. In the transition from proprietary to open source technology in the industry, CAMIS can serve as a guidebook to navigate this process.\n\nkeywords: cross industry collaboration, multi-lingua, open-source, quarto"
  },
  {
    "objectID": "rpkg/qtwAcademic/index.html",
    "href": "rpkg/qtwAcademic/index.html",
    "title": "qtwAcademic",
    "section": "",
    "text": "qtwAcademic stands for Quarto Websites for Academics, which provides a few Quarto templates for Quarto website that are commonly used by academics.\nThe templates are designed to make it quick and easy for users with little or no Quarto experience to create a website for their personal portfolio or courses. Each template is fully customizable once the user is more familiar with Quarto.\nRead more about the package here.\n\nTemplates\nSo far, 3 templates have been implemented in this package:\n\nPersonal website\nWebsite for courses or workshops\nMinimal website template that can be easily customized\n\nYou can find more details on each option in the vignettes."
  },
  {
    "objectID": "rpkg/noreden/index.html",
    "href": "rpkg/noreden/index.html",
    "title": "noreden",
    "section": "",
    "text": "This package provides tools to facilitate sustainable diet discovery.\nGitHub Link"
  },
  {
    "objectID": "rpkg/medicode/index.html",
    "href": "rpkg/medicode/index.html",
    "title": "medicode",
    "section": "",
    "text": "This package provides metadata and tools for medical classification and clinical coding.\nGitHub Link\nIt is especially useful for English and Norwegian (Bokmål) languages.\nPlanned content:\n\nICD-10\nICPC-2\nEuropean shortlist for Cause of Death"
  },
  {
    "objectID": "rpkg/cstime/index.html",
    "href": "rpkg/cstime/index.html",
    "title": "cstime",
    "section": "",
    "text": "cstime provides convenient and consistent conversion between\n\nisoyear\nisoweek\ncalyear\nseason week (used in influenza surveillance)\n\nGitHub link"
  },
  {
    "objectID": "rpkg/csdata/index.html",
    "href": "rpkg/csdata/index.html",
    "title": "csdata",
    "section": "",
    "text": "https://github.com/csids/csdata"
  },
  {
    "objectID": "rpkg/covidnor/index.html",
    "href": "rpkg/covidnor/index.html",
    "title": "covidnor",
    "section": "",
    "text": "https://github.com/csids/covidnor"
  },
  {
    "objectID": "research/workshop_WB/index.html",
    "href": "research/workshop_WB/index.html",
    "title": "Western Blot",
    "section": "",
    "text": "Western Blot是一种基于抗原-抗体特异性结合的分子生物学技术，用于检测特定蛋白质的存在、相对丰度及分子量。其核心原理包括以下三部分：\n\nSDS-PAGE电泳分离\n\nSDS（十二烷基硫酸钠）：破坏蛋白质的非共价键，使蛋白质变性为线性结构，并均匀包裹负电荷（电荷与质量比相同）。\nPAGE（聚丙烯酰胺凝胶电泳）：利用凝胶的孔径筛作用，根据蛋白质分子量大小进行分离（小分子迁移快，大分子迁移慢）。\n\n蛋白质转移至固相膜\n\n通过电转移（湿转或半干转）将凝胶中的蛋白质转移到PVDF膜或NC膜上，固定蛋白质以供后续检测。\n\n抗体识别与显色/发光\n\n一抗：特异性识别目标蛋白。\n二抗：标记有HRP（辣根过氧化物酶）或荧光素，与一抗结合后通过化学发光、显色或荧光成像显示目标蛋白位置。\n\n\n\n\n\n\n\n\n\n细胞/组织裂解\n\n裂解液选择：\n\n普通细胞：RIPA裂解液（含1% PMSF）。\n难溶蛋白：加入1% SDS或NP-40。\n磷酸化蛋白：需添加磷酸酶抑制剂（如Na₃VO₄、NaF）。\n\n裂解条件：\n\n动物组织：30分钟内处理，切块冻存（-80℃）。\n植物样本：液氮研磨，保留健康组织。\n裂解后离心（4℃，12000-15000 rpm，10-15 min）取上清。\n\n\n蛋白定量\n\nBCA法：标准品复孔，样品稀释5-10倍，37℃孵育30 min，562 nm读数（R²&gt;0.99）。\nBradford法：适用于可溶蛋白，但可能受不可溶蛋白干扰。\n\n变性处理\n\n加入5×loading buffer（比例1:4），100℃煮沸10-20 min，使蛋白完全变性。\n\n\n\n\n\n\n\n凝胶制备\n\n分离胶浓度选择：\n\n小分子量蛋白（&lt;30 kDa）：12-15%胶。\n中等分子量（30-70 kDa）：8-12%胶。\n大分子量（&gt;70 kDa）：6-8%胶。\n\n灌胶步骤：\n\n分离胶灌注后加水封胶，凝固后吸去水层。\n浓缩胶（5%）灌注并插入梳子，凝固后拔除梳子形成上样孔。\n\n\n电泳条件\n\n浓缩胶：80 V，30-40 min（使样品压缩成线）。\n分离胶：120 V，1-1.5 h（根据蛋白大小调整时间）。\n注意事项：电泳缓冲液需预冷，避免高温导致“微笑条带”。\n\n\n\n\n\n\n\n膜选择\n\nPVDF膜：机械强度高，适合多次剥脱，需甲醇活化。\nNC膜：信噪比高，无需甲醇预处理，但不适合含SDS的转膜缓冲液。\n\n转膜步骤\n\n转膜缓冲液：含甲醇（20%），预冷至4℃。\n转膜装置：组装“三明治”（-海绵→滤纸→凝胶→膜→滤纸→海绵+），确保无气泡。\n转膜参数：\n\n30 kDa以下：30 min，220 mA。\n30-70 kDa：60-90 min，220 mA。\n70-150 kDa：90-180 min，220 mA。\n\n验证转膜：丽春红染色或考马斯亮蓝染色观察蛋白转移效果。\n\n\n\n\n\n\n\n封闭\n\n5%脱脂牛奶/TBST：室温1 h，阻断非特异性结合位点。\n快速封闭液：可缩短封闭时间（如10 min）。\n\n一抗孵育\n\n稀释比例：根据抗体说明书（如1:1000）。\n孵育条件：室温1 h或4℃过夜（需覆盖膜防止干燥）。\n\n二抗孵育\n\nHRP标记二抗：稀释比例1:5000，室温1 h避光孵育。\n荧光标记二抗：适用于多色检测，需配合成像系统。\n\n洗涤\n\nTBST/PBST：室温摇洗3次，每次10 min，去除未结合抗体。\n\n\n\n\n\n\n\n化学发光法（ECL）\n\n显色时间：常规底物1 min，高性能底物（如SuperSignal）5 min。\n成像：使用X光胶片或化学发光成像仪（推荐后者，灵敏度更高）。\n\n显色法（DAB）\n\n适用于低丰度蛋白，但可能产生背景干扰。\n\n荧光法\n\n多色检测时需使用兼容的荧光成像系统。\n\n\n\n\n\n\n\n\n样本处理\n\n新鲜样本优先：动物组织30分钟内处理，植物样本去除枯黄部分。\n冻存规范：分装≤1 g，加入RNAlater防降解，标记清晰。\n\n裂解液与抑制剂\n\n现用现加抑制剂：蛋白酶/磷酸酶抑制剂需在使用前加入裂解液。\n裂解时间控制：细胞裂解30 min，组织匀浆2 h（4℃）。\n\n电泳与转膜优化\n\n凝胶选择：根据蛋白分子量选择梯度胶或均一胶。\n转膜效率：避免高电压导致膜破损，必要时使用预染Marker监控转膜。\n\n抗体使用\n\n稀释比例：根据抗体说明书调整，避免过高浓度过高背景。\n对照设置：阳性/阴性对照（如内参蛋白GAPDH、β-Actin）确保特异性。\n\n背景控制\n\n封闭充分：避免非特异性结合。\n内源IgG干扰：使用TidyBlot试剂（仅结合完整IgG）减少背景。\n\n定量与重复\n\nBCA/Braford：确保上样量一致（20-40 μg总蛋白）。\n重复实验：至少3次独立实验验证结果可靠性。\n\n设备与耗材\n\n低温操作：离心机、电泳槽提前预冷，防止蛋白降解。\n膜保存：未使用的膜密封于-20℃，避免潮解。\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n问题\n可能原因\n解决方案\n\n\n\n\n条带模糊或无信号\n蛋白变性不完全、转膜失败\n延长煮样时间，优化转膜参数\n\n\n高背景信号\n封闭不充分、抗体浓度过高\n增加封闭时间，降低抗体稀释比例\n\n\n条带位置异常\n蛋白修饰（如磷酸化）、凝胶孔径不适\n使用非还原条件，调整凝胶浓度\n\n\n转膜不均\n凝胶与膜之间有气泡\n重新组装转膜装置，排除气泡\n\n\n内参蛋白信号弱\n上样量不足、内参抗体失效\n增加上样量，验证内参抗体有效性\n\n\n\n\n\n\n\nWestern Blot是蛋白分析的“金标准”，其成功依赖于严谨的样本处理、精确的电泳与转膜条件以及特异性抗体的合理使用。通过优化每一步骤（如裂解液配制、定量方法、抗体稀释），可显著提高实验重复性和数据可靠性。对于复杂样本（如组织裂解物），需特别注意内源干扰和背景控制。掌握这些细节，才能高效完成高质量的Western Blot实验。"
  },
  {
    "objectID": "research/workshop_WB/index.html#western-blot蛋白质免疫印迹",
    "href": "research/workshop_WB/index.html#western-blot蛋白质免疫印迹",
    "title": "Western Blot",
    "section": "",
    "text": "Western Blot是一种基于抗原-抗体特异性结合的分子生物学技术，用于检测特定蛋白质的存在、相对丰度及分子量。其核心原理包括以下三部分：\n\nSDS-PAGE电泳分离\n\nSDS（十二烷基硫酸钠）：破坏蛋白质的非共价键，使蛋白质变性为线性结构，并均匀包裹负电荷（电荷与质量比相同）。\nPAGE（聚丙烯酰胺凝胶电泳）：利用凝胶的孔径筛作用，根据蛋白质分子量大小进行分离（小分子迁移快，大分子迁移慢）。\n\n蛋白质转移至固相膜\n\n通过电转移（湿转或半干转）将凝胶中的蛋白质转移到PVDF膜或NC膜上，固定蛋白质以供后续检测。\n\n抗体识别与显色/发光\n\n一抗：特异性识别目标蛋白。\n二抗：标记有HRP（辣根过氧化物酶）或荧光素，与一抗结合后通过化学发光、显色或荧光成像显示目标蛋白位置。\n\n\n\n\n\n\n\n\n\n细胞/组织裂解\n\n裂解液选择：\n\n普通细胞：RIPA裂解液（含1% PMSF）。\n难溶蛋白：加入1% SDS或NP-40。\n磷酸化蛋白：需添加磷酸酶抑制剂（如Na₃VO₄、NaF）。\n\n裂解条件：\n\n动物组织：30分钟内处理，切块冻存（-80℃）。\n植物样本：液氮研磨，保留健康组织。\n裂解后离心（4℃，12000-15000 rpm，10-15 min）取上清。\n\n\n蛋白定量\n\nBCA法：标准品复孔，样品稀释5-10倍，37℃孵育30 min，562 nm读数（R²&gt;0.99）。\nBradford法：适用于可溶蛋白，但可能受不可溶蛋白干扰。\n\n变性处理\n\n加入5×loading buffer（比例1:4），100℃煮沸10-20 min，使蛋白完全变性。\n\n\n\n\n\n\n\n凝胶制备\n\n分离胶浓度选择：\n\n小分子量蛋白（&lt;30 kDa）：12-15%胶。\n中等分子量（30-70 kDa）：8-12%胶。\n大分子量（&gt;70 kDa）：6-8%胶。\n\n灌胶步骤：\n\n分离胶灌注后加水封胶，凝固后吸去水层。\n浓缩胶（5%）灌注并插入梳子，凝固后拔除梳子形成上样孔。\n\n\n电泳条件\n\n浓缩胶：80 V，30-40 min（使样品压缩成线）。\n分离胶：120 V，1-1.5 h（根据蛋白大小调整时间）。\n注意事项：电泳缓冲液需预冷，避免高温导致“微笑条带”。\n\n\n\n\n\n\n\n膜选择\n\nPVDF膜：机械强度高，适合多次剥脱，需甲醇活化。\nNC膜：信噪比高，无需甲醇预处理，但不适合含SDS的转膜缓冲液。\n\n转膜步骤\n\n转膜缓冲液：含甲醇（20%），预冷至4℃。\n转膜装置：组装“三明治”（-海绵→滤纸→凝胶→膜→滤纸→海绵+），确保无气泡。\n转膜参数：\n\n30 kDa以下：30 min，220 mA。\n30-70 kDa：60-90 min，220 mA。\n70-150 kDa：90-180 min，220 mA。\n\n验证转膜：丽春红染色或考马斯亮蓝染色观察蛋白转移效果。\n\n\n\n\n\n\n\n封闭\n\n5%脱脂牛奶/TBST：室温1 h，阻断非特异性结合位点。\n快速封闭液：可缩短封闭时间（如10 min）。\n\n一抗孵育\n\n稀释比例：根据抗体说明书（如1:1000）。\n孵育条件：室温1 h或4℃过夜（需覆盖膜防止干燥）。\n\n二抗孵育\n\nHRP标记二抗：稀释比例1:5000，室温1 h避光孵育。\n荧光标记二抗：适用于多色检测，需配合成像系统。\n\n洗涤\n\nTBST/PBST：室温摇洗3次，每次10 min，去除未结合抗体。\n\n\n\n\n\n\n\n化学发光法（ECL）\n\n显色时间：常规底物1 min，高性能底物（如SuperSignal）5 min。\n成像：使用X光胶片或化学发光成像仪（推荐后者，灵敏度更高）。\n\n显色法（DAB）\n\n适用于低丰度蛋白，但可能产生背景干扰。\n\n荧光法\n\n多色检测时需使用兼容的荧光成像系统。\n\n\n\n\n\n\n\n\n样本处理\n\n新鲜样本优先：动物组织30分钟内处理，植物样本去除枯黄部分。\n冻存规范：分装≤1 g，加入RNAlater防降解，标记清晰。\n\n裂解液与抑制剂\n\n现用现加抑制剂：蛋白酶/磷酸酶抑制剂需在使用前加入裂解液。\n裂解时间控制：细胞裂解30 min，组织匀浆2 h（4℃）。\n\n电泳与转膜优化\n\n凝胶选择：根据蛋白分子量选择梯度胶或均一胶。\n转膜效率：避免高电压导致膜破损，必要时使用预染Marker监控转膜。\n\n抗体使用\n\n稀释比例：根据抗体说明书调整，避免过高浓度过高背景。\n对照设置：阳性/阴性对照（如内参蛋白GAPDH、β-Actin）确保特异性。\n\n背景控制\n\n封闭充分：避免非特异性结合。\n内源IgG干扰：使用TidyBlot试剂（仅结合完整IgG）减少背景。\n\n定量与重复\n\nBCA/Braford：确保上样量一致（20-40 μg总蛋白）。\n重复实验：至少3次独立实验验证结果可靠性。\n\n设备与耗材\n\n低温操作：离心机、电泳槽提前预冷，防止蛋白降解。\n膜保存：未使用的膜密封于-20℃，避免潮解。\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n问题\n可能原因\n解决方案\n\n\n\n\n条带模糊或无信号\n蛋白变性不完全、转膜失败\n延长煮样时间，优化转膜参数\n\n\n高背景信号\n封闭不充分、抗体浓度过高\n增加封闭时间，降低抗体稀释比例\n\n\n条带位置异常\n蛋白修饰（如磷酸化）、凝胶孔径不适\n使用非还原条件，调整凝胶浓度\n\n\n转膜不均\n凝胶与膜之间有气泡\n重新组装转膜装置，排除气泡\n\n\n内参蛋白信号弱\n上样量不足、内参抗体失效\n增加上样量，验证内参抗体有效性\n\n\n\n\n\n\n\nWestern Blot是蛋白分析的“金标准”，其成功依赖于严谨的样本处理、精确的电泳与转膜条件以及特异性抗体的合理使用。通过优化每一步骤（如裂解液配制、定量方法、抗体稀释），可显著提高实验重复性和数据可靠性。对于复杂样本（如组织裂解物），需特别注意内源干扰和背景控制。掌握这些细节，才能高效完成高质量的Western Blot实验。"
  },
  {
    "objectID": "research/workshop_WB/index.html#western-blot样本制备的原理与方法步骤",
    "href": "research/workshop_WB/index.html#western-blot样本制备的原理与方法步骤",
    "title": "Western Blot",
    "section": "Western Blot样本制备的原理与方法步骤",
    "text": "Western Blot样本制备的原理与方法步骤\n\n\n一、原理\nWestern Blot样本制备的核心目标是高效释放细胞或组织中的蛋白质，同时保持其完整性和活性，以便后续的电泳分离和检测。具体原理包括：\n\n裂解细胞/组织\n\n通过裂解液破坏细胞膜和细胞器，释放蛋白质。裂解液通常含去垢剂（如SDS、Triton X-100）和盐类，以溶解膜结构。\n\n抑制蛋白降解\n\n添加蛋白酶抑制剂（如PMSF、EDTA）和磷酸酶抑制剂（如Na₃VO₄），防止蛋白酶或磷酸酶在裂解过程中降解目标蛋白或修饰其活性。\n\n定量与变性处理\n\n通过蛋白定量（如BCA法）确定样品浓度，确保上样量一致；加入SDS-PAGE上样缓冲液使蛋白质变性，便于电泳分离。\n\n\n\n\n\n二、方法步骤\n\n1. 细胞裂解\n（1）悬浮细胞\n\n步骤：\n\n离心收集细胞（1000-1500 rpm，5 min）。\n用PBS洗涤1-2次，去除培养液中的血清和杂质。\n加入裂解液（如RIPA裂解液，含蛋白酶/磷酸酶抑制剂），冰上裂解30 min。\n若裂解不充分，可冰浴超声辅助裂解。\n离心（4℃，12000-15000 rpm，10-15 min），取上清液用于后续实验。\n\n\n（2）贴壁细胞\n\n步骤：\n\n吸净培养液，用PBS洗涤1-2次。\n加入裂解液直接裂解（或胰酶消化后按悬浮细胞处理，但需注意胰酶可能降解某些蛋白）。\n冰上裂解30 min，离心后取上清。\n\n\n（3）裂解液选择\n\n常规裂解液：RIPA（含1% Triton X-100、0.1% SDS）。\n难溶蛋白：添加1% SDS或NP-40。\n磷酸化蛋白：需额外添加磷酸酶抑制剂（如Na₃VO₄、NaF）。\n\n\n\n\n2. 组织裂解\n（1）预处理\n\n去除非目标成分：洗净血液、脂肪等（尤其对脾脏、心脏等富含IgG的组织）。\n灌流处理：实验动物可通过心脏灌注生理盐水（含PMSF），使组织颜色变白后再采集。\n\n（2）破碎方法\n\n匀浆法：\n\n按比例加入裂解液（如1:5组织重量:裂解液体积）。\n使用玻璃匀浆器或电动匀浆器匀浆至无明显组织块。\n\n研磨法：\n\n液氮冷冻组织后，在研钵中研磨成粉末。\n加入裂解液裂解，混合均匀。\n\n\n（3）离心与上清收集\n\n4℃离心（12000-15000 rpm，10-15 min），取上清液。\n\n\n\n\n3. 蛋白定量\n（1）BCA法\n\n原理：蛋白质在碱性条件下将Cu²⁺还原为Cu⁺，与BCA试剂反应生成紫色复合物，562 nm比色。\n步骤：\n\n制作标准曲线（BSA梯度稀释）。\n样品稀释5-10倍，与BCA工作液混合，37℃孵育30 min。\n测定吸光度（R²&gt;0.99时可靠）。\n\n\n（2）Bradford法\n\n原理：考马斯亮蓝G-250染料与蛋白质结合后发生颜色变化（465-595 nm）。\n优点：快速、灵敏，适合可溶蛋白；但易受不可溶蛋白干扰。\n\n\n\n\n4. 变性处理\n\n目的：使蛋白质完全变性，消除空间结构对电泳的影响。\n步骤：\n\n加入5×SDS-PAGE上样缓冲液（1:4体积比）。\n100℃煮沸10-20 min，或55℃加热30 min（避免高温降解敏感蛋白）。\n冰浴冷却后进行电泳。\n\n\n\n\n\n三、关键注意事项\n\n防止蛋白降解\n\n全程低温操作（冰上裂解、4℃离心）。\n裂解液中必须现加蛋白酶/磷酸酶抑制剂。\n\n分装与保存\n\n裂解液和样品避免反复冻融，分装后-80℃保存。\n\n组织处理技巧\n\n富含IgG的组织（如脾脏）需充分洗涤，避免内源抗体干扰。\n液氮研磨适用于难裂解组织，但需注意研磨均匀性。\n\n裂解效率优化\n\n难裂解细胞可尝试超声破碎或增加裂解液浓度。\n胰酶消化可能导致蛋白片段化，需根据实验需求权衡。\n\n\n\n\n\n四、常见问题与解决方案\n\n\n\n\n\n\n\n\n问题\n可能原因\n解决方案\n\n\n\n\n蛋白浓度偏低\n裂解不充分、组织未破碎完全\n增加裂解时间，改用液氮研磨\n\n\n高背景信号\n内源IgG干扰（如脾脏组织）\n充分洗涤组织，使用低IgG裂解液\n\n\n蛋白降解\n蛋白酶抑制剂失效或操作过热\n现加抑制剂，全程低温操作\n\n\n上样量不一致\n定量误差\n重复BCA/Bradford测定，取平均值"
  },
  {
    "objectID": "research/research.html",
    "href": "research/research.html",
    "title": "科研",
    "section": "",
    "text": "主要是我的各种科研笔记，目前只有文献阅读"
  },
  {
    "objectID": "research/research.html#文献",
    "href": "research/research.html#文献",
    "title": "科研",
    "section": "文献",
    "text": "文献\n\n\n\n\n\n\nTitle\n\n\n\nDescription\n\n\n\ntype\n\n\n\nDate\n\n\n\n\n\n\n\n\nClinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations\n\n\n程毅松2024年2月15发表于Artif Intell Med\n\n\nclinical\n\n\n8/27/25\n\n\n\n\n\n\nDual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii\n\n\n康焰2024年3月30发表于J Nanobiotechnology\n\n\nbasic\n\n\n8/27/25\n\n\n\n\n\n\nMachine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit\n\n\n程毅松2022年125日发表于Chin Med J (Engl)\n\n\nclinical\n\n\n8/27/25\n\n\n\n\n\n\nRespiratory effort monitoring: a novel, bedside, non-invasive, real-time method.\n\n\n康焰2025年7月3日发表于Critical care (London, England)\n\n\nclinical\n\n\n8/27/25\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "research/research.html#workshops",
    "href": "research/research.html#workshops",
    "title": "科研",
    "section": "Workshops",
    "text": "Workshops\n\n\n\n\n\n\nTitle\n\n\n\nDescription\n\n\n\ntype\n\n\n\n\n\n\n\n\nWestern Blot\n\n\nWB的相关知识，我觉得面试可能会问到的\n\n\nexperiment\n\n\n\n\n\n\n单细胞测序\n\n\n单细胞测序的相关知识，我觉得面试可能会问到的\n\n\nbioinformatics\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "research/research.html#guides-and-cheatsheets",
    "href": "research/research.html#guides-and-cheatsheets",
    "title": "科研",
    "section": "Guides and Cheatsheets",
    "text": "Guides and Cheatsheets\n\n\n\nTitle\nDescription\n\n\n\n\nggplot2\nLecture notes for ggplot2 at the Carpentries workshop, UiO\n\n\nlist of commands\nQuick reference list of R commands used in my statistics classes"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html",
    "href": "research/literature_kangyan_20240330/index.html",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "多重耐药鲍曼不动杆菌（MDR Acinetobacter baumannii）是神经外科术后颅内感染的主要致病菌，其高死亡率（高达71%）和传统抗生素（如替加环素，TGC）的血脑屏障（BBB）渗透性差，限制了治疗效果。\n因此，开发一种能高效递送抗生素至脑部的靶向递送系统至关重要。\n\n\n\n\n双靶向纳米载体设计：\n\n开发了一种核-壳结构纳米颗粒（Aβ11/T80@CSs），通过Aβ11肽（靶向血脑屏障的低密度脂蛋白受体相关蛋白1，LRP1）和Tween 80（增强纳米颗粒在脑内皮细胞的积累）双重修饰，提高药物在脑部的靶向性。\n使用mPEG-PLGA/PLGA材料包裹水溶性替加环素（TGC），解决其半衰期短和血脑屏障渗透性差的问题。\n\n\n\n\n\n\n\n\n核-壳结构纳米颗粒（Aβ11/T80@CSs）\n\n\n\n\n\n\n核心成分：mPEG-PLGA/PLGA包裹水溶性替加环素（TGC），解决其半衰期短和血脑屏障渗透性差的问题。\n壳层修饰：\n\nAβ11肽：靶向血脑屏障上的低密度脂蛋白受体相关蛋白1（LRP1），促进纳米颗粒跨膜转运。\nTween 80：表面活性剂，通过改变纳米颗粒表面电荷和疏水性，增强其在脑内皮细胞的积累。\n\n优势：双靶向策略显著提高药物在脑部的富集效率。\n\n\n\n\n\n关键性能验证：\n\n体外实验：\n\n纳米颗粒粒径约158 nm，包封效率达84.2%，并能通过透析法实现持续药物释放（12小时内释放80%以上）。\n在bEnd.3脑内皮细胞模型中，Aβ11/T80@CSs的细胞摄取率比单靶向或未修饰组高3.9倍，且跨膜转运能力显著增强。\n\n体内实验：\n\n在MDR鲍曼不动杆菌颅内感染大鼠模型中，Aβ11/T80@CSs-TGC组的脑脊液（CSF）抗菌率高达90%，显著优于游离TGC组（抗菌率不足50%）。\n药代动力学分析显示，纳米颗粒可延长TGC的血浆半衰期（AUC_0-8h为游离TGC的2.5倍），并降低其清除率（CL降低2.76倍）。\n\n\n安全性评估：\n\n溶血率：&lt;5%（与阳性对照相比），表明纳米颗粒对红细胞无显著毒性。\n细胞毒性和组织病理学：bEnd.3细胞存活率&gt;80%，且对心、肝、脾、肺、肾等器官无明显病理损伤，证明其生物相容性良好。\n\n\n\n\n\n\n解决临床难题：\n\n首次提出Aβ11/T80双靶向策略，成功克服血脑屏障，为颅内感染治疗提供新思路。\n纳米颗粒的高效递送使TGC在脑部达到有效浓度，显著抑制MDR鲍曼不动杆菌的生长。\n\n技术突破：\n\n核-壳纳米颗粒的稳定性和可控释放特性（12小时内持续释放80%药物）为水溶性抗生素的脑靶向递送提供了可行方案。\n\n临床转化潜力：\n\n研究为脑靶向纳米载体系统在颅内感染及其他中枢神经系统疾病中的应用奠定了基础，未来可通过优化靶向配体或联合其他抗生素进一步开发。\n\n\n\n\n\n\n局限性：\n\n目前仅在动物模型中验证，需进一步开展临床试验评估人体安全性和疗效。\n纳米颗粒的长期毒性及在复杂病理环境下的稳定性需深入研究。\n\n未来方向：\n\n探索Aβ11/T80双靶向系统在其他耐药菌（如铜绿假单胞菌、耐药革兰氏阳性菌）颅内感染中的应用。\n结合基因治疗或免疫调节策略，开发多功能纳米药物递送平台。\n\n\n\n\n\n本研究通过双靶向纳米颗粒设计，成功解决了替加环素在颅内感染治疗中的血脑屏障难题，显著提升了药物疗效和安全性。这一成果为耐药菌引起的中枢神经系统感染提供了创新的治疗策略，并推动了纳米医学在临床转化中的应用。"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html#背景",
    "href": "research/literature_kangyan_20240330/index.html#背景",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "多重耐药鲍曼不动杆菌（MDR Acinetobacter baumannii）是神经外科术后颅内感染的主要致病菌，其高死亡率（高达71%）和传统抗生素（如替加环素，TGC）的血脑屏障（BBB）渗透性差，限制了治疗效果。\n因此，开发一种能高效递送抗生素至脑部的靶向递送系统至关重要。"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html#研究创新点",
    "href": "research/literature_kangyan_20240330/index.html#研究创新点",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "双靶向纳米载体设计：\n\n开发了一种核-壳结构纳米颗粒（Aβ11/T80@CSs），通过Aβ11肽（靶向血脑屏障的低密度脂蛋白受体相关蛋白1，LRP1）和Tween 80（增强纳米颗粒在脑内皮细胞的积累）双重修饰，提高药物在脑部的靶向性。\n使用mPEG-PLGA/PLGA材料包裹水溶性替加环素（TGC），解决其半衰期短和血脑屏障渗透性差的问题。\n\n\n\n\n\n\n\n\n核-壳结构纳米颗粒（Aβ11/T80@CSs）\n\n\n\n\n\n\n核心成分：mPEG-PLGA/PLGA包裹水溶性替加环素（TGC），解决其半衰期短和血脑屏障渗透性差的问题。\n壳层修饰：\n\nAβ11肽：靶向血脑屏障上的低密度脂蛋白受体相关蛋白1（LRP1），促进纳米颗粒跨膜转运。\nTween 80：表面活性剂，通过改变纳米颗粒表面电荷和疏水性，增强其在脑内皮细胞的积累。\n\n优势：双靶向策略显著提高药物在脑部的富集效率。\n\n\n\n\n\n关键性能验证：\n\n体外实验：\n\n纳米颗粒粒径约158 nm，包封效率达84.2%，并能通过透析法实现持续药物释放（12小时内释放80%以上）。\n在bEnd.3脑内皮细胞模型中，Aβ11/T80@CSs的细胞摄取率比单靶向或未修饰组高3.9倍，且跨膜转运能力显著增强。\n\n体内实验：\n\n在MDR鲍曼不动杆菌颅内感染大鼠模型中，Aβ11/T80@CSs-TGC组的脑脊液（CSF）抗菌率高达90%，显著优于游离TGC组（抗菌率不足50%）。\n药代动力学分析显示，纳米颗粒可延长TGC的血浆半衰期（AUC_0-8h为游离TGC的2.5倍），并降低其清除率（CL降低2.76倍）。\n\n\n安全性评估：\n\n溶血率：&lt;5%（与阳性对照相比），表明纳米颗粒对红细胞无显著毒性。\n细胞毒性和组织病理学：bEnd.3细胞存活率&gt;80%，且对心、肝、脾、肺、肾等器官无明显病理损伤，证明其生物相容性良好。"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html#研究意义与贡献",
    "href": "research/literature_kangyan_20240330/index.html#研究意义与贡献",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "解决临床难题：\n\n首次提出Aβ11/T80双靶向策略，成功克服血脑屏障，为颅内感染治疗提供新思路。\n纳米颗粒的高效递送使TGC在脑部达到有效浓度，显著抑制MDR鲍曼不动杆菌的生长。\n\n技术突破：\n\n核-壳纳米颗粒的稳定性和可控释放特性（12小时内持续释放80%药物）为水溶性抗生素的脑靶向递送提供了可行方案。\n\n临床转化潜力：\n\n研究为脑靶向纳米载体系统在颅内感染及其他中枢神经系统疾病中的应用奠定了基础，未来可通过优化靶向配体或联合其他抗生素进一步开发。"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html#局限性与展望",
    "href": "research/literature_kangyan_20240330/index.html#局限性与展望",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "局限性：\n\n目前仅在动物模型中验证，需进一步开展临床试验评估人体安全性和疗效。\n纳米颗粒的长期毒性及在复杂病理环境下的稳定性需深入研究。\n\n未来方向：\n\n探索Aβ11/T80双靶向系统在其他耐药菌（如铜绿假单胞菌、耐药革兰氏阳性菌）颅内感染中的应用。\n结合基因治疗或免疫调节策略，开发多功能纳米药物递送平台。"
  },
  {
    "objectID": "research/literature_kangyan_20240330/index.html#结论",
    "href": "research/literature_kangyan_20240330/index.html#结论",
    "title": "Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii",
    "section": "",
    "text": "本研究通过双靶向纳米颗粒设计，成功解决了替加环素在颅内感染治疗中的血脑屏障难题，显著提升了药物疗效和安全性。这一成果为耐药菌引起的中枢神经系统感染提供了创新的治疗策略，并推动了纳米医学在临床转化中的应用。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html",
    "href": "research/literature_chengyisong_20221205/index.html",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "急性肾损伤（AKI）是急性胰腺炎患者在重症监护病房（ICU）中常见的严重并发症。\n发生AKI的急性胰腺炎患者死亡率显著高于未发生者。\n目前AKI的诊断依赖血清肌酐升高或尿量减少，但这些指标出现时肾脏损害已发生，缺乏早期预警能力。\n\n\n\n\n\n建立基于机器学习算法和传统逻辑回归（LR）模型的预测模型，仅使用患者进入ICU时常规采集的临床变量，预测其后续是否会发生AKI。\n比较不同模型的预测性能，评估机器学习在该场景下的优势。\n\n\n\n\n\n研究设计与数据来源：\n\n回顾性队列研究，数据来自四川大学华西医院ICU 2015年12月至2019年12月收治的急性胰腺炎患者。\n纳入标准：确诊为急性胰腺炎、年龄≥18岁、入住ICU。\n排除标准：\n\n入ICU时已诊断AKI；\n有慢性肾病史；\n胰腺肿瘤、外伤或慢性胰腺炎；\n年龄&lt;18岁。\n\n\n诊断标准：\n\n急性胰腺炎：符合以下三项中至少两项：\n\n典型腹痛；\n淀粉酶或脂肪酶升高至正常上限3倍以上；\n影像学支持。\n\nAKI：依据KDIGO指南，基于血清肌酐变化或尿量定义。\n\n数据划分与模型训练：\n\n将数据按7:3比例分为训练集（70%）和测试集（30%），避免样本重复使用。\n采用10折交叉验证优化模型稳定性。\n使用网格搜索（Grid Search）进行超参数调优。\n\n建模方法：\n\n传统模型：逻辑回归（Logistic Regression, LR）\n\n先进行单变量分析筛选P&lt;0.05的变量；\n再进行多变量逐步回归（forward stepwise），构建最终LR模型；\n建立预测列线图（Nomogram）。\n\n机器学习模型：\n\n选择三种集成学习算法：梯度提升（GB）、随机森林（RF）、极端梯度提升（XGB）。\n这些模型具有较高预测精度且具备一定可解释性。\n\n\n模型评估指标：\n\n主要指标：AUC（曲线下面积）\n其他指标：\n\n净重分类改善指数（NRI）\n综合判别改善指数（IDI）\n决策曲线分析（DCA）——评估临床实用性\n\n\n\n\n\n\n\n患者基本情况：\n\n共纳入488例患者，其中151例（30.9%）发生AKI。\nAKI组患者白细胞、中性粒细胞、肌酐、尿酸、BNP、D-二聚体、PCT、CRP等炎症和器官功能指标更高，ICU住院时间更长，28天死亡率更高。\n\n多变量分析结果（LR模型）：\n\n独立预测因子包括：\n\n血清肌酐（OR=1.004, P&lt;0.001）\n前降钙素（PCT）（OR=1.024, P=0.004）\n自然对数转换的BNP（Ln BNP）（OR=1.010, P=0.013）\n\n\n模型性能比较（AUC）：\n\n逻辑回归（LR）：0.763\n梯度提升（GB）：0.828\n随机森林（RF）：0.812\n极端梯度提升（XGB）：0.809\n所有机器学习模型AUC均高于LR，但差异未达到统计学显著性（P&gt;0.05）\n\n其他评估指标：\n\nNRI 和 IDI：所有机器学习模型均表现出显著的净重分类和判别能力提升（P&lt;0.05）。\n决策曲线分析（DCA）：\n\n当阈值概率低于约0.4时，机器学习模型的净收益明显优于LR模型。\n表明在临床决策中，机器学习模型能更准确识别高风险患者。\n\n\n\n\n\n\n决策曲线\n\n\n\n特征重要性分析（以GB模型为例）：\n\nSHAP值分析显示最重要的前5个预测变量为：\n\n血清肌酐\n尿酸\n前降钙素（PCT）\n凝血酶时间（TT）\nBNP\n\n提示这些指标在预测AKI中具有关键作用。\n\n\n\n\n\n\n本研究成功构建了三种机器学习模型（GB、RF、XGB）和一个传统逻辑回归模型，用于预测急性胰腺炎患者入住ICU后发生AKI的风险。\n尽管机器学习模型在AUC上的提升未达统计学显著性，但在净重分类（NRI/IDI）和临床净收益（DCA）方面显著优于传统LR模型。\n因此，机器学习方法整体上优于传统建模方式，具备更强的临床应用潜力。\n\n\n\n\n\n单中心回顾性研究，样本量相对较小（n=488），可能影响模型泛化能力。\n缺乏外部验证数据集，限制了模型的普适性。\n部分重要临床变量缺失，如：\n\n尿量动态变化\n合并症\n慢性用药情况\n治疗干预信息\n\n仅使用入ICU时的数据进行预测，未考虑时间序列变化；\n\n且未明确AKI诊断的具体时间，因此无法评估“提前预测”的时间窗口。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#背景",
    "href": "research/literature_chengyisong_20221205/index.html#背景",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "急性肾损伤（AKI）是急性胰腺炎患者在重症监护病房（ICU）中常见的严重并发症。\n发生AKI的急性胰腺炎患者死亡率显著高于未发生者。\n目前AKI的诊断依赖血清肌酐升高或尿量减少，但这些指标出现时肾脏损害已发生，缺乏早期预警能力。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#目的",
    "href": "research/literature_chengyisong_20221205/index.html#目的",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "建立基于机器学习算法和传统逻辑回归（LR）模型的预测模型，仅使用患者进入ICU时常规采集的临床变量，预测其后续是否会发生AKI。\n比较不同模型的预测性能，评估机器学习在该场景下的优势。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#研究方法",
    "href": "research/literature_chengyisong_20221205/index.html#研究方法",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "研究设计与数据来源：\n\n回顾性队列研究，数据来自四川大学华西医院ICU 2015年12月至2019年12月收治的急性胰腺炎患者。\n纳入标准：确诊为急性胰腺炎、年龄≥18岁、入住ICU。\n排除标准：\n\n入ICU时已诊断AKI；\n有慢性肾病史；\n胰腺肿瘤、外伤或慢性胰腺炎；\n年龄&lt;18岁。\n\n\n诊断标准：\n\n急性胰腺炎：符合以下三项中至少两项：\n\n典型腹痛；\n淀粉酶或脂肪酶升高至正常上限3倍以上；\n影像学支持。\n\nAKI：依据KDIGO指南，基于血清肌酐变化或尿量定义。\n\n数据划分与模型训练：\n\n将数据按7:3比例分为训练集（70%）和测试集（30%），避免样本重复使用。\n采用10折交叉验证优化模型稳定性。\n使用网格搜索（Grid Search）进行超参数调优。\n\n建模方法：\n\n传统模型：逻辑回归（Logistic Regression, LR）\n\n先进行单变量分析筛选P&lt;0.05的变量；\n再进行多变量逐步回归（forward stepwise），构建最终LR模型；\n建立预测列线图（Nomogram）。\n\n机器学习模型：\n\n选择三种集成学习算法：梯度提升（GB）、随机森林（RF）、极端梯度提升（XGB）。\n这些模型具有较高预测精度且具备一定可解释性。\n\n\n模型评估指标：\n\n主要指标：AUC（曲线下面积）\n其他指标：\n\n净重分类改善指数（NRI）\n综合判别改善指数（IDI）\n决策曲线分析（DCA）——评估临床实用性"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#结果",
    "href": "research/literature_chengyisong_20221205/index.html#结果",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "患者基本情况：\n\n共纳入488例患者，其中151例（30.9%）发生AKI。\nAKI组患者白细胞、中性粒细胞、肌酐、尿酸、BNP、D-二聚体、PCT、CRP等炎症和器官功能指标更高，ICU住院时间更长，28天死亡率更高。\n\n多变量分析结果（LR模型）：\n\n独立预测因子包括：\n\n血清肌酐（OR=1.004, P&lt;0.001）\n前降钙素（PCT）（OR=1.024, P=0.004）\n自然对数转换的BNP（Ln BNP）（OR=1.010, P=0.013）\n\n\n模型性能比较（AUC）：\n\n逻辑回归（LR）：0.763\n梯度提升（GB）：0.828\n随机森林（RF）：0.812\n极端梯度提升（XGB）：0.809\n所有机器学习模型AUC均高于LR，但差异未达到统计学显著性（P&gt;0.05）\n\n其他评估指标：\n\nNRI 和 IDI：所有机器学习模型均表现出显著的净重分类和判别能力提升（P&lt;0.05）。\n决策曲线分析（DCA）：\n\n当阈值概率低于约0.4时，机器学习模型的净收益明显优于LR模型。\n表明在临床决策中，机器学习模型能更准确识别高风险患者。\n\n\n\n\n\n\n决策曲线\n\n\n\n特征重要性分析（以GB模型为例）：\n\nSHAP值分析显示最重要的前5个预测变量为：\n\n血清肌酐\n尿酸\n前降钙素（PCT）\n凝血酶时间（TT）\nBNP\n\n提示这些指标在预测AKI中具有关键作用。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#结论",
    "href": "research/literature_chengyisong_20221205/index.html#结论",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "本研究成功构建了三种机器学习模型（GB、RF、XGB）和一个传统逻辑回归模型，用于预测急性胰腺炎患者入住ICU后发生AKI的风险。\n尽管机器学习模型在AUC上的提升未达统计学显著性，但在净重分类（NRI/IDI）和临床净收益（DCA）方面显著优于传统LR模型。\n因此，机器学习方法整体上优于传统建模方式，具备更强的临床应用潜力。"
  },
  {
    "objectID": "research/literature_chengyisong_20221205/index.html#局限性",
    "href": "research/literature_chengyisong_20221205/index.html#局限性",
    "title": "Machine learning for the prediction of acute kidney injury in patients with acute pancreatitis admitted to the intensive care unit",
    "section": "",
    "text": "单中心回顾性研究，样本量相对较小（n=488），可能影响模型泛化能力。\n缺乏外部验证数据集，限制了模型的普适性。\n部分重要临床变量缺失，如：\n\n尿量动态变化\n合并症\n慢性用药情况\n治疗干预信息\n\n仅使用入ICU时的数据进行预测，未考虑时间序列变化；\n\n且未明确AKI诊断的具体时间，因此无法评估“提前预测”的时间窗口。"
  },
  {
    "objectID": "projects/sykdomspulsen/index.html",
    "href": "projects/sykdomspulsen/index.html",
    "title": "CSIDS",
    "section": "",
    "text": "CSIDS: the Consortium for Statistics in Disease Surveillance (previously Sykdomspulsen) is a real-time analysis and disease surveillance system designed and developed at the Norwegian Institute of Public Health (NIPH/FHI). It is a unique project that processes new data (e.g. covid-19 cases) shortly after it is available. Complex statistical analyses are automatically run for all locations in Norway, producing reports and alerting various stakeholders. This provides the health authorities the ability to make proactive strategic decisions with the most up-to-date information.\n\n\ncsverse is a number of R packages that have been developed by the Sykdomspulsen team to help with infectious diseases surveillance.\n\n\n\nIn November 2022, the core components of Sykdomspulsen and splverse R packages have been migrated to CSIDS: the Consortium for Statistics in Disease Surveillance. Please refer to CSIDS for ongoing developments.\n\n\n\n\nWe receive data from more than 15 data sources every day\n2 000 000 000+ rows of data and results (1TB)\n1 000+ database tables\n1 000 000+ analyses per day\n1 000+ automatic reports per day\n\n\n\nDownload poster (Norwegian)"
  },
  {
    "objectID": "projects/sykdomspulsen/index.html#overview",
    "href": "projects/sykdomspulsen/index.html#overview",
    "title": "CSIDS",
    "section": "",
    "text": "CSIDS: the Consortium for Statistics in Disease Surveillance (previously Sykdomspulsen) is a real-time analysis and disease surveillance system designed and developed at the Norwegian Institute of Public Health (NIPH/FHI). It is a unique project that processes new data (e.g. covid-19 cases) shortly after it is available. Complex statistical analyses are automatically run for all locations in Norway, producing reports and alerting various stakeholders. This provides the health authorities the ability to make proactive strategic decisions with the most up-to-date information.\n\n\ncsverse is a number of R packages that have been developed by the Sykdomspulsen team to help with infectious diseases surveillance.\n\n\n\nIn November 2022, the core components of Sykdomspulsen and splverse R packages have been migrated to CSIDS: the Consortium for Statistics in Disease Surveillance. Please refer to CSIDS for ongoing developments.\n\n\n\n\nWe receive data from more than 15 data sources every day\n2 000 000 000+ rows of data and results (1TB)\n1 000+ database tables\n1 000 000+ analyses per day\n1 000+ automatic reports per day\n\n\n\nDownload poster (Norwegian)"
  },
  {
    "objectID": "projects/phuse/index.html",
    "href": "projects/phuse/index.html",
    "title": "PHUSE - CAMIS",
    "section": "",
    "text": "I am contributing to two working groups at PHUSE: CAMIS, and RWD - Real World Data Guideline (early stage).\n\nCAMIS: Comparing Analysis Method Implementations in Software\nCAMIS is a cross-industry group formed of members from PHUSE, PSI and ASA.\nSeveral discrepancies have been discovered in statistical analysis results between different programming languages, even in fully qualified statistical computing environments. Observing differences across languages can reduce the analyst’s confidence in reliability and, by understanding the source of any discrepancies, one can reinstate confidence in reliability.\nThe goal of this project is to demystify conflict when doing QC and to help ease the transitions to new languages and techniques with comparison and comprehensive explanations.\n\n\nRWD Working Group\nThis is a newly formed working group, working on statistical programming guidelines while working on RWD (read world data)."
  },
  {
    "objectID": "projects/nor_mortality/index.html",
    "href": "projects/nor_mortality/index.html",
    "title": "Mortality Surveillance in Norway",
    "section": "",
    "text": "NorMOMO"
  },
  {
    "objectID": "projects/nor_mortality/index.html#norwegian-surveillance-system-for-excess-mortality",
    "href": "projects/nor_mortality/index.html#norwegian-surveillance-system-for-excess-mortality",
    "title": "Mortality Surveillance in Norway",
    "section": "",
    "text": "NorMOMO"
  },
  {
    "objectID": "projects/nor_mortality/index.html#r-packages-for-mortality-surveillance",
    "href": "projects/nor_mortality/index.html#r-packages-for-mortality-surveillance",
    "title": "Mortality Surveillance in Norway",
    "section": "R packages for mortality surveillance",
    "text": "R packages for mortality surveillance\n(continue…)\n\nnowcast\nsplalert\nmortanor"
  },
  {
    "objectID": "projects/nor_mortality/index.html#collaboration-with-cause-of-death-registry",
    "href": "projects/nor_mortality/index.html#collaboration-with-cause-of-death-registry",
    "title": "Mortality Surveillance in Norway",
    "section": "Collaboration with Cause of Death Registry",
    "text": "Collaboration with Cause of Death Registry"
  },
  {
    "objectID": "projects/ehr/index.html",
    "href": "projects/ehr/index.html",
    "title": "ggehr",
    "section": "",
    "text": "ggehr (read: gg E-H-R) stands for ggplot2 extension for EHR data, which provides a set of tools to facilitate EHR (Electronic Health Records) visualization.\nggehr package helps you make visualize EHR data, so that you can\n\nhave an overview of the mixed type information related to a patient;\nvisually identify the errors in data recording.\n\nLearn more about ggehr"
  },
  {
    "objectID": "misc/literature.html",
    "href": "misc/literature.html",
    "title": "笑面狐",
    "section": "",
    "text": "antibiotics stewardship\ninfections (community, hospital)\nelectronic health records\nquality assurance: prescripton and use"
  },
  {
    "objectID": "misc/literature.html#ab-x-ehr",
    "href": "misc/literature.html#ab-x-ehr",
    "title": "笑面狐",
    "section": "AB x EHR",
    "text": "AB x EHR\nMoehring 2021, EHR identify AB use among hospitalized patients\nReenggli 2021: assess EHR conversion into AB stewardship indicators\nCairns 2021: integrate AB stewardship with EHR in australia\nJenkins 2022: AB stewardship using electornic prescribing systems, review of intervention and outcome measures\nKuijpers 2024, excessive length of AB duration for HAI, support AB stewardship high relevance"
  },
  {
    "objectID": "misc/literature.html#ehr-doctor-experience-system-design",
    "href": "misc/literature.html#ehr-doctor-experience-system-design",
    "title": "笑面狐",
    "section": "EHR doctor experience, system design",
    "text": "EHR doctor experience, system design\nOstrer 2023, real time benefit tools must be designed to serve both clinicians and patients. mentions burden\nKawamoto 2019 Association of EHR add-on app for neonatal bilirubin management, physician efficiency and care quality. Good system and add-on can save clinician time and improve patient care.\nTsai 2020, EHR implementation, barriers to adoption and use high relevance\nOverhage 2020, time spent using EHR\n\nburnout\nTajirian 2020, influence of EHR on physician burnout high relevance\nKhairat 2020, EHR use with physician fatigue and efficiency\nKroth 2019, factors of EHR design and use for physician stress and burnout high relevance\nMelnick 2020, EHR usability, task load and burnout high relevance\nHilliard 2020, factors associated with burnout\nMore on this topic\nhttps://www.sciencedirect.com/science/article/abs/pii/S0897189718301356\nhttps://journals.sagepub.com/doi/full/10.1177/20552076231220241\nhttps://jamanetwork.com/journals/jamanetworkopen/article-abstract/2778909\n\n\nDesign\nGascon 2013 the process of designing a EHR lab request module\nTorres 2017, effect of EHR design on documentation and compliance high relevance"
  },
  {
    "objectID": "misc/literature.html#ehr-data-quality-use-for-prediction-model-development",
    "href": "misc/literature.html#ehr-data-quality-use-for-prediction-model-development",
    "title": "笑面狐",
    "section": "EHR data quality, use for prediction model development",
    "text": "EHR data quality, use for prediction model development\n\nerror\nbell 2020\nhttps://www.sciencedirect.com/science/article/abs/pii/S2213076420300439\nLi 2024, comparison of error reporting systems. 82% undetected, 90% had no corresponding incident report, some errors not reported at all\nWestbrook 2020, changes in medication administration error rates, associated with EHR\nGildon 2019, impact of EHR on prescribing errors in pediatric clinics. introduction is relevant for pointing out the need for well designed system\nGinzburg 2018, use clinical decision support within EHR to reduce incorrect prescribing for acute sinusitis. shows prompt for physicians to fill in reason for why AB is required high relevance\n\n\nbias\nGianfrancesco 2018, potential biases in ML algorithms using EHR data. Existing EHR disparities should not be amplified by thoughtless or excess reliance on machines.\nAgniel 2018, biases in EHR due to process within the healthcare system. healthcare processes must be addressed in the analysis of observational health data, context is important. high relevance\nBower, biases in EHR based surveillance of cardiovascular disease risk\nHarding2024, addressing common sources of bias in type 2 diabetes following covid, using EHR\nBica 2020, current and future methods to address underlying challenges from EHR to treatment effects mid relevance to manuscript, but important to myself\nDesai 2020, prediction using admin EHR, hear failure"
  },
  {
    "objectID": "misc/literature.html#ab-stewardship-not-so-relevant",
    "href": "misc/literature.html#ab-stewardship-not-so-relevant",
    "title": "笑面狐",
    "section": "AB stewardship (not so relevant)",
    "text": "AB stewardship (not so relevant)\nRenggli 2021: consumption of anti-meticillin resistant staphylococcus aureus antibiotics in Swiss hospitals is associateed with antibiotic stewardship measures\nVaughn 2021: AB overuse and stewardship at hospital discharge\nGraber 2019: electronic tools to decrease AB use"
  },
  {
    "objectID": "dev/short_bio.html",
    "href": "dev/short_bio.html",
    "title": "笑面狐",
    "section": "",
    "text": "Chi Zhang is a statistician and R developer at the Faculty of Medicine, University of Oslo in Norway. Since 2016, She has been working with Real World Data such as Electronic Health Records (EHR) and large public health registries. In 2020-2022 she worked as part of the COVID emergency response team at Norwegian Institute of Public Health to develop an open source real-time analysis and public health surveillance system. At the moment Chi is collaborating with Oslo University Hospital and Akershus University Hospital on understanding antibiotics prescription and usage recorded in the EHR system. She develops R packages to facilitate exploration of messy EHR data. Outside research and R package development, She teaches statistics courses using R and Quarto. Chi is a Co-lead of the CAMIS project (Comparing Analysis Method Implementations in Software) and has contributed to various chapters to RWD Guideline for Programming and Analysis Processes."
  },
  {
    "objectID": "blog/learnnotes_words/index.html",
    "href": "blog/learnnotes_words/index.html",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Shock 休克\nTrauma /ˈtrɔːmə/ 创伤\nVentricular /venˈtrɪkjələ(r)/ Fibrillation /ˌfɪbrɪˈleɪʃən/ 室颤\nAcute Respiratory /rəˈspɪrət(ə)ri/ Distress Syndrome(ARDS) 急性呼吸窘迫综合征\nAcute Myocardial /ˌmaɪəʊˈkɑːdiəl/ Infarction /ɪnˈfɑːkʃn/, AMI 急性心肌梗死\nHeart Failure, HF 心力衰竭\nRight ventricular /venˈtrɪkjələ(r)/ failure 右心衰竭\nRespiratory failure 呼吸衰竭\nRenal /ˈriːnl/ failure 肾衰竭\nAcute Kidney Injury (AKI) 急性肾损伤\nEncephalopathy /enˌsefəˈlɒpəθi; enˌkefəˈlɒpəθi/ 脑病\nDisseminated /dɪˈsemɪneɪtɪd/ Intravascular /ˌɪntrəˈvæskjʊlə(r)/ Coagulation /kəʊˌæɡjuˈleɪʃ(ə)n/ (DIC) 弥散性血管内凝血\nCOPD 慢性阻塞性肺疾病\nsepsis 脓毒症\nseptic shock感染性休克\nDelirium /dɪˈlɪriəm; dɪˈlɪəriəm/ 谵妄\nSIRS 全身炎症反应综合征\nOrgan dysfunction 器官功能障碍\nMultiple Organ Dysfunction Syndrome, MODS 多器官功能障碍综合征\nDeep vein thrombosis /θrɒmˈbəʊsɪs/ (DVT) 深静脉血栓\ndrowning 淹溺\nelectrical injury电击伤\nMultiple Injuries 多发性创伤\nPoisoning 急性中毒\nCompartment Syndrome 挤压综合征\nHeat Stroke 热射病\nAltitude Sickness 高原反应\nHypothermia 低体温\nLeukocytosis /ˌluːkəʊsaɪˈtəʊsɪs/ 白细胞增多\nThrombocytopenia /,θrɒmbə(ʊ),saɪtə(ʊ)’piːnɪə/ 血小板减少症\nhospital-acquired infection 医院获得性感染\nCatheter-related bloodstream infection (CRBSI) 导管相关血流感染\nVentilator-associated pneumonia /njuːˈməʊniə/ (VAP) 呼吸机相关肺炎\nMultidrug-resistant organism (MDRO) 多重耐药菌\nRefractory /rɪ’frækt(ə)rɪ/ septic shock 难治性感染性休克\nHypertensive emergency 高血压急症\nNon-ST elevation /,elɪ’veɪʃ(ə)n/ myocardial /,maɪəʊ’kɑːdɪəl/ infarction /ɪn’fɑːkʃ(ə)n/ (NSTEMI) 非ST段抬高型心肌梗死\nPost-ICU Syndrome, PICS ICU后综合征\n\n\n\nCPR 心肺复苏\nAED 自动体外除颤器\nACLS 高级心血管支持\n\n\n\nMechanical Ventilation /,ventɪ’leɪʃ(ə)n/ 机械通气\nNon-invasive ventilation (NIV) 无创通气\nProne /prəʊn/ Positioning 俯卧位通气\nAirway Management 气道管理\nHigh-Flow Oxygen Therapy 高流量氧疗\nWeaning from Mechanical Ventilation 机械通气脱机\nNebulizer /’nebjulaizə/ Therapy 雾化吸入治疗\nFluid Resuscitation /rɪˌsʌsɪˈteɪʃ(ə)n/ 液体复苏\nQuantitative resuscitation 定量复苏\nsedation /sɪˈdeɪʃn/ 镇静\nSedation management 镇静管理\nanalgesia /,æn(ə)l’dʒiːzɪə/ 镇痛\nGlucose /ˈɡluːkəʊs/ control 血糖控制\nRenal replacement therapy (RRT) 肾脏替代治疗\nContinuous Renal Replacement Therapy (CRRT) 连续性肾脏替代治疗\nExtracorporeal Membrane Oxygenation (ECMO) 体外膜肺氧合\nIntra-Aortic /eɪˈɔːtɪk/ Balloon Pump (IABP) 主动脉球囊反搏\nSpontaneous Awakening Trial (SAT) 自主唤醒实验\nTracheostomy /,træki’ɔstəmi, ,trei-/ 气管造口术\nElectroencephalogram (EEG) 脑电图\nThoracentesis /θɔ:rəsen’ti:sis/ 胸腔穿刺\nParacentesis /ˌpærəsenˈtiːsɪs/ 腹腔穿刺术\nArtificial airway management 人工气道管理\nPressure injury prevention 压疮预防\nInsulin /ˈɪnsjəlɪn/ therapy 胰岛素治疗\nLung-protective ventilation 肺保护性通气策略\nDelayed RRT 延迟肾脏替代治疗\nEarly enteral nutrition 早期肠内营养\nAnticoagulation /kəʊˌæɡjuˈleɪʃ(ə)n/ therapy 抗凝治疗\nTransfusion 输血\nPlatelet /’pleɪtlɪt/ transfusion 血小板输注\nComponent Transfusion 成分输血\nAntibiotic stewardship /ˈstjuːədʃɪp/ 抗生素管理\nContact precautions 解除隔离措施\nPercutaneous /ˌpɜːkjuːˈteɪniəs/ coronary /ˈkɔːrəneri/ intervention (PCI) 经皮冠状动脉介入治疗\nUltrasound-guided procedures 超声引导下操作\nPercutaneous endoscopic gastrostomy (PEG) 经皮内镜下胃造口术\nUltrasound-guided central line placement 超声引导下中心静脉置管\nSepsis Bundle /’bʌnd(ə)l/ 脓毒症集束化治疗\nVAP Bundle 呼吸机相关性肺炎预防集束化措施\neCASH Bundle 早期舒适化镇痛镇静集束化方案\nHemodynamic Optimization /,ɒptɪmaɪ’zeɪʃən/ Protocol 血流动力学优化方案\nStem cell therapy for ARDS 干细胞治疗急性呼吸窘迫综合征\nImmunomodulatory therapy 免疫调节治疗\nHypothermia therapy 亚低温治疗\nCritical Care Nutrition 危重症营养\nPalliative /ˈpæliətɪv/ care 姑息治疗\nPlasma Exchange, PE 血浆置换\nImmunoadsorption 免疫吸附\nCitrate Anticoagulation 枸橼酸抗凝\nEarly Mobilization /ˌməʊbɪlaɪˈzeɪʃn/ 早期活动\nGoal-Directed Fluid Therapy, GDFT 目标导向的液体治疗\nHypothermia Therapy 低温治疗\nUrinary /’jʊərɪn(ə)rɪ/ Catheter Care 导尿管护理\nDressing Change 敷料更换\nIV Access Maintenance 静脉通路维护\n\n\n\nVentilator 呼吸机\nBedside monitor 床旁监护仪\nDefibrillator /di’faibrileitə/ 除颤仪\nHemodialysis /,hiːmədaɪ’ælɪsɪs/ machine 血液净化机\nInfusion pump/Microinfusion pump 输液泵/微量泵\nCooling blanket 降温毯\nPoint-of-care ultrasound 床旁超声\nArterial /ɑː’tɪərɪəl/ line 动脉导管\nCentral venous /ˈviːnəs/ catheter /’kæθɪtə/ 中心静脉导管\nExtracorporeal /ˌekstrəkɔːˈpɔːriəl/ Life Support (ECLS) 体外生命支持（包括ECMO）\nExtracorporeal Liver Support 体外肝支持\nExtracorporeal Membrane Oxygenation, ECMO 体外膜肺氧合\nClosed-loop insulin delivery system 闭环胰岛素输注系统\nChest tube 胸腔闭式引流管\nCrash cart 急救车\nSwan-Ganz Catheter 右心导管\nWeaning /wiːn/ from ventilator 撤机\n\n\n\nantibiotics /,æntɪbaɪ’ɒtɪks/ 抗生素\nCiprofloxacin /,siprəu’flɔksəsin/ 环丙沙星\nMetronidazole /,metrə’naɪdəzəʊl/ 甲硝唑\nMeropenem 美罗培南\nImipenem 亚胺培南\nTeicoplanin 替考拉宁\nVancomycin 万古霉素\nInotropes 正性肌力药\nCorticosteroid /ˌkɔːtɪkəʊˈstɪərɔɪd/ 糖皮质激素\nGlucocorticoids /,glu:kəu’kɔ:ti,kɔid/ 糖皮质激素\nDexamethasone /ˌdeksəˈmeθəˌsəʊn/ 地塞米松\nTheophylline /,θi:ə’fili:n; -in; ,θiə-; θi’ɔfilin/ 茶碱\nDexmedetomidine 右美托咪定\nPropofol 丙泊酚\nMidazolam 咪达唑仑\nPancuronium 泮库溴铵\nNaloxone /nəˈlɒksəʊn/ 纳洛酮\nVasoactive /ˌveɪzəʊˈæktɪv/ Drugs 血管活性药物\nVasopressors /ˌveɪzəʊˈpresə(r)/ 血管活性药物\nVasopressin /ˌvæsəʊˈpresɪn/ 血管加压素\nEpinephrine /ˌepɪˈnefrɪn/ 肾上腺素\nNorepinephrine /ˌnɔːrepɪˈnefrɪn; -riːn/ 去甲肾上腺素\nDobutamine /dəʊ’bjuːtəmiːn/ 多巴酚丁胺\nDopamine /’dəʊpəmiːn/ 多巴胺\nNitroglycerin /ˌnaɪtrəʊˈɡlɪsərɪn; ˌnaɪtrəʊˈɡlɪsəriːn/ 硝酸甘油\nSodium Nitroprusside 硝普纳\nFurosemide /ˈfjʊərˌəʊsəˌmaɪd/ 呋塞米\nSedative-analgesic /ˈsedətɪv//ˌænəlˈdʒiːzɪk/ agents 镇静镇痛药\nInsulin 胰岛素\nAlbumin /ˈælbjʊmɪn/ 白蛋白\nFresh frozen plasma (FFP) 新鲜冰冻血浆\nrhAPC 重组人活化蛋白C\nHepcidin 铁调素\nAmiodarone /,æmiəu’dærəu/ 胺碘酮\nAtropine /ˈætrəpɪn/ 阿托品\nSodium Bicarbonate 碳酸氢钠\nCalcium /ˈkælsiəm/ Gluconate /ˈɡluːkəˌneɪt/ 葡萄糖酸钙\nProtamine 鱼精蛋白\nHeparin /’hepərɪn/ 肝素\nWarfarin /’wɔːfərɪn/ 华法林\nSuccinylcholine 琥珀酰胆碱\n\n\n\nArterial /ɑːˈtɪəriəl/ blood gas，ABG 动脉血气分析\nEndotracheal /ˌendəʊˈtreɪkɪəl/ intubation 气管插管\nVital signs monitoring 生命体征监测\nHemodynamic monitoring 血流动力学监测\nProcalcitonin (PCT) 降钙素原\nSequential Organ Failure Assessment (SOFA) 序贯器官衰竭评估\nLactic acid/lactate 乳酸\ncreatinine 肌酐\nuric acid 尿酸\nserum creatinine 血清肌酐\namylase 淀粉酶\nlipase 脂肪酶\nBrain natriuretic peptide (BNP) 脑钠肽\nGlasgow /’ɡlɑ:sɡəu/ Coma /’kəʊmə/ Scale (GCS) 格拉斯哥昏迷评分\nAcute Physiology /,fɪzɪ’ɒlədʒɪ/ and Chronic Health Evaluation (APACHE) 急性生理慢性健康评分\nSimplified Acute Physiology Score (SAPS) 简化急性生理学评分\nCriteria /kraɪ’tɪərɪə/ 标准\nAKIN Criteria 急性肾损伤网络标准\nLactate clearance rate 乳酸清除率\nCentral venous pressure (CVP) 中心静脉压\nCerebral /səˈriːbrəl/ perfusion pressure (CPP) 脑灌注压\nSystemic vascular resistance (SVR) 体循环血管阻力\nPulmonary /ˈpʌlmənəri/ artery 肺动脉\nCoagulation profile 凝血功能检查\nFluid challenge 液体冲击试验\nMixed venous oxygen saturation (SvO₂) 混合静脉血氧饱和度\nOxygenation index 氧合指数\nPaO₂/FiO₂ 氧合指数\nEnd-Tidal Carbon Dioxide, ETCO₂ 呼气末二氧化碳\nNeurocritical care 神经重症监护\nCerebral Oxygen Monitoring 脑氧监测\nColony-Stimulating Factor, CSF 集落刺激因子\nIntestinal /ˌɪnˈtestɪnəl/ Barrier Function Monitoring 肠屏障功能监测\nContinuous EEG Monitoring 连续性神经电监测\nExtravascular Lung Water Index, EVLWI 血管外肺水指数\nCardiac index 心脏指数\nEnteral Nutrition Tolerance 肠内营养耐受评估\nSedation Depth Monitoring 镇静深度评估\nPain Assessment 疼痛评估\n\n\n\n1. hx - History（病史）\n2. dx - Diagnosis（诊断）\n3. tx - Treatment（治疗）\n4. sx - Symptoms（症状）\n5. fx - Fracture（骨折）\n6. px - Prognosis（预后）\n\n\n\nIntensive Care Unit，ICU 重症监护室\nMultidisciplinary team (MDT) 多学科协作团队\nEnd-of-life care 临终关怀\nEthical decision-making 伦理决策\nEthics Committee Review 伦理委员会审查\nPatient autonomy /ɔːˈtɒnəmi/ 患者自主权\nFutility /fju:’tiliti/ of care 无效医疗\nDo-not-resuscitate (DNR) 放弃心肺复苏\nbrain death 脑死亡\nSurrogate /’sʌrəgət/ decision-making 替代决策\nPalliative /’pælɪətɪv/ care integration 姑息治疗整合\nEnd-of-life discussions 临终讨论\nTrauma team activation 创伤团队启动\nCardiac arrest team 心脏骤停团队\nTransplant ICU 抑制重症监护室\nNeurocritical care 神经重症\n\n\n\nMachine learning in sepsis prediction 机器学习在脓毒症预测中的应用\nGut Microbiota Modulation 肠道菌群调控\nGene Editing 基因编辑技术\nNanomedicine Delivery 纳米药物递送\nMetabolomics /metæˈbɑːləmɪks/ 代谢组学\nProteomics /ˌprəʊtɪˈɒmɪks/ 蛋白组学\nSingle-Cell Sequencing 单细胞测序\n\n\n\ndeviate /ˈdiːvieɪt/ 偏离\noptimal 最优的\ncomply [kəmˈplaɪ] 遵从，服从\nfungal 真菌的\nregimen 方案、疗程\nanesthetic [ˌænəsˈθetɪk] 麻醉剂、麻醉的"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#疾病",
    "href": "blog/learnnotes_words/index.html#疾病",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Shock 休克\nTrauma /ˈtrɔːmə/ 创伤\nVentricular /venˈtrɪkjələ(r)/ Fibrillation /ˌfɪbrɪˈleɪʃən/ 室颤\nAcute Respiratory /rəˈspɪrət(ə)ri/ Distress Syndrome(ARDS) 急性呼吸窘迫综合征\nAcute Myocardial /ˌmaɪəʊˈkɑːdiəl/ Infarction /ɪnˈfɑːkʃn/, AMI 急性心肌梗死\nHeart Failure, HF 心力衰竭\nRight ventricular /venˈtrɪkjələ(r)/ failure 右心衰竭\nRespiratory failure 呼吸衰竭\nRenal /ˈriːnl/ failure 肾衰竭\nAcute Kidney Injury (AKI) 急性肾损伤\nEncephalopathy /enˌsefəˈlɒpəθi; enˌkefəˈlɒpəθi/ 脑病\nDisseminated /dɪˈsemɪneɪtɪd/ Intravascular /ˌɪntrəˈvæskjʊlə(r)/ Coagulation /kəʊˌæɡjuˈleɪʃ(ə)n/ (DIC) 弥散性血管内凝血\nCOPD 慢性阻塞性肺疾病\nsepsis 脓毒症\nseptic shock感染性休克\nDelirium /dɪˈlɪriəm; dɪˈlɪəriəm/ 谵妄\nSIRS 全身炎症反应综合征\nOrgan dysfunction 器官功能障碍\nMultiple Organ Dysfunction Syndrome, MODS 多器官功能障碍综合征\nDeep vein thrombosis /θrɒmˈbəʊsɪs/ (DVT) 深静脉血栓\ndrowning 淹溺\nelectrical injury电击伤\nMultiple Injuries 多发性创伤\nPoisoning 急性中毒\nCompartment Syndrome 挤压综合征\nHeat Stroke 热射病\nAltitude Sickness 高原反应\nHypothermia 低体温\nLeukocytosis /ˌluːkəʊsaɪˈtəʊsɪs/ 白细胞增多\nThrombocytopenia /,θrɒmbə(ʊ),saɪtə(ʊ)’piːnɪə/ 血小板减少症\nhospital-acquired infection 医院获得性感染\nCatheter-related bloodstream infection (CRBSI) 导管相关血流感染\nVentilator-associated pneumonia /njuːˈməʊniə/ (VAP) 呼吸机相关肺炎\nMultidrug-resistant organism (MDRO) 多重耐药菌\nRefractory /rɪ’frækt(ə)rɪ/ septic shock 难治性感染性休克\nHypertensive emergency 高血压急症\nNon-ST elevation /,elɪ’veɪʃ(ə)n/ myocardial /,maɪəʊ’kɑːdɪəl/ infarction /ɪn’fɑːkʃ(ə)n/ (NSTEMI) 非ST段抬高型心肌梗死\nPost-ICU Syndrome, PICS ICU后综合征"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#急救与复苏",
    "href": "blog/learnnotes_words/index.html#急救与复苏",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "CPR 心肺复苏\nAED 自动体外除颤器\nACLS 高级心血管支持"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#治疗",
    "href": "blog/learnnotes_words/index.html#治疗",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Mechanical Ventilation /,ventɪ’leɪʃ(ə)n/ 机械通气\nNon-invasive ventilation (NIV) 无创通气\nProne /prəʊn/ Positioning 俯卧位通气\nAirway Management 气道管理\nHigh-Flow Oxygen Therapy 高流量氧疗\nWeaning from Mechanical Ventilation 机械通气脱机\nNebulizer /’nebjulaizə/ Therapy 雾化吸入治疗\nFluid Resuscitation /rɪˌsʌsɪˈteɪʃ(ə)n/ 液体复苏\nQuantitative resuscitation 定量复苏\nsedation /sɪˈdeɪʃn/ 镇静\nSedation management 镇静管理\nanalgesia /,æn(ə)l’dʒiːzɪə/ 镇痛\nGlucose /ˈɡluːkəʊs/ control 血糖控制\nRenal replacement therapy (RRT) 肾脏替代治疗\nContinuous Renal Replacement Therapy (CRRT) 连续性肾脏替代治疗\nExtracorporeal Membrane Oxygenation (ECMO) 体外膜肺氧合\nIntra-Aortic /eɪˈɔːtɪk/ Balloon Pump (IABP) 主动脉球囊反搏\nSpontaneous Awakening Trial (SAT) 自主唤醒实验\nTracheostomy /,træki’ɔstəmi, ,trei-/ 气管造口术\nElectroencephalogram (EEG) 脑电图\nThoracentesis /θɔ:rəsen’ti:sis/ 胸腔穿刺\nParacentesis /ˌpærəsenˈtiːsɪs/ 腹腔穿刺术\nArtificial airway management 人工气道管理\nPressure injury prevention 压疮预防\nInsulin /ˈɪnsjəlɪn/ therapy 胰岛素治疗\nLung-protective ventilation 肺保护性通气策略\nDelayed RRT 延迟肾脏替代治疗\nEarly enteral nutrition 早期肠内营养\nAnticoagulation /kəʊˌæɡjuˈleɪʃ(ə)n/ therapy 抗凝治疗\nTransfusion 输血\nPlatelet /’pleɪtlɪt/ transfusion 血小板输注\nComponent Transfusion 成分输血\nAntibiotic stewardship /ˈstjuːədʃɪp/ 抗生素管理\nContact precautions 解除隔离措施\nPercutaneous /ˌpɜːkjuːˈteɪniəs/ coronary /ˈkɔːrəneri/ intervention (PCI) 经皮冠状动脉介入治疗\nUltrasound-guided procedures 超声引导下操作\nPercutaneous endoscopic gastrostomy (PEG) 经皮内镜下胃造口术\nUltrasound-guided central line placement 超声引导下中心静脉置管\nSepsis Bundle /’bʌnd(ə)l/ 脓毒症集束化治疗\nVAP Bundle 呼吸机相关性肺炎预防集束化措施\neCASH Bundle 早期舒适化镇痛镇静集束化方案\nHemodynamic Optimization /,ɒptɪmaɪ’zeɪʃən/ Protocol 血流动力学优化方案\nStem cell therapy for ARDS 干细胞治疗急性呼吸窘迫综合征\nImmunomodulatory therapy 免疫调节治疗\nHypothermia therapy 亚低温治疗\nCritical Care Nutrition 危重症营养\nPalliative /ˈpæliətɪv/ care 姑息治疗\nPlasma Exchange, PE 血浆置换\nImmunoadsorption 免疫吸附\nCitrate Anticoagulation 枸橼酸抗凝\nEarly Mobilization /ˌməʊbɪlaɪˈzeɪʃn/ 早期活动\nGoal-Directed Fluid Therapy, GDFT 目标导向的液体治疗\nHypothermia Therapy 低温治疗\nUrinary /’jʊərɪn(ə)rɪ/ Catheter Care 导尿管护理\nDressing Change 敷料更换\nIV Access Maintenance 静脉通路维护"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#仪器设备",
    "href": "blog/learnnotes_words/index.html#仪器设备",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Ventilator 呼吸机\nBedside monitor 床旁监护仪\nDefibrillator /di’faibrileitə/ 除颤仪\nHemodialysis /,hiːmədaɪ’ælɪsɪs/ machine 血液净化机\nInfusion pump/Microinfusion pump 输液泵/微量泵\nCooling blanket 降温毯\nPoint-of-care ultrasound 床旁超声\nArterial /ɑː’tɪərɪəl/ line 动脉导管\nCentral venous /ˈviːnəs/ catheter /’kæθɪtə/ 中心静脉导管\nExtracorporeal /ˌekstrəkɔːˈpɔːriəl/ Life Support (ECLS) 体外生命支持（包括ECMO）\nExtracorporeal Liver Support 体外肝支持\nExtracorporeal Membrane Oxygenation, ECMO 体外膜肺氧合\nClosed-loop insulin delivery system 闭环胰岛素输注系统\nChest tube 胸腔闭式引流管\nCrash cart 急救车\nSwan-Ganz Catheter 右心导管\nWeaning /wiːn/ from ventilator 撤机"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#药物",
    "href": "blog/learnnotes_words/index.html#药物",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "antibiotics /,æntɪbaɪ’ɒtɪks/ 抗生素\nCiprofloxacin /,siprəu’flɔksəsin/ 环丙沙星\nMetronidazole /,metrə’naɪdəzəʊl/ 甲硝唑\nMeropenem 美罗培南\nImipenem 亚胺培南\nTeicoplanin 替考拉宁\nVancomycin 万古霉素\nInotropes 正性肌力药\nCorticosteroid /ˌkɔːtɪkəʊˈstɪərɔɪd/ 糖皮质激素\nGlucocorticoids /,glu:kəu’kɔ:ti,kɔid/ 糖皮质激素\nDexamethasone /ˌdeksəˈmeθəˌsəʊn/ 地塞米松\nTheophylline /,θi:ə’fili:n; -in; ,θiə-; θi’ɔfilin/ 茶碱\nDexmedetomidine 右美托咪定\nPropofol 丙泊酚\nMidazolam 咪达唑仑\nPancuronium 泮库溴铵\nNaloxone /nəˈlɒksəʊn/ 纳洛酮\nVasoactive /ˌveɪzəʊˈæktɪv/ Drugs 血管活性药物\nVasopressors /ˌveɪzəʊˈpresə(r)/ 血管活性药物\nVasopressin /ˌvæsəʊˈpresɪn/ 血管加压素\nEpinephrine /ˌepɪˈnefrɪn/ 肾上腺素\nNorepinephrine /ˌnɔːrepɪˈnefrɪn; -riːn/ 去甲肾上腺素\nDobutamine /dəʊ’bjuːtəmiːn/ 多巴酚丁胺\nDopamine /’dəʊpəmiːn/ 多巴胺\nNitroglycerin /ˌnaɪtrəʊˈɡlɪsərɪn; ˌnaɪtrəʊˈɡlɪsəriːn/ 硝酸甘油\nSodium Nitroprusside 硝普纳\nFurosemide /ˈfjʊərˌəʊsəˌmaɪd/ 呋塞米\nSedative-analgesic /ˈsedətɪv//ˌænəlˈdʒiːzɪk/ agents 镇静镇痛药\nInsulin 胰岛素\nAlbumin /ˈælbjʊmɪn/ 白蛋白\nFresh frozen plasma (FFP) 新鲜冰冻血浆\nrhAPC 重组人活化蛋白C\nHepcidin 铁调素\nAmiodarone /,æmiəu’dærəu/ 胺碘酮\nAtropine /ˈætrəpɪn/ 阿托品\nSodium Bicarbonate 碳酸氢钠\nCalcium /ˈkælsiəm/ Gluconate /ˈɡluːkəˌneɪt/ 葡萄糖酸钙\nProtamine 鱼精蛋白\nHeparin /’hepərɪn/ 肝素\nWarfarin /’wɔːfərɪn/ 华法林\nSuccinylcholine 琥珀酰胆碱"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#监测",
    "href": "blog/learnnotes_words/index.html#监测",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Arterial /ɑːˈtɪəriəl/ blood gas，ABG 动脉血气分析\nEndotracheal /ˌendəʊˈtreɪkɪəl/ intubation 气管插管\nVital signs monitoring 生命体征监测\nHemodynamic monitoring 血流动力学监测\nProcalcitonin (PCT) 降钙素原\nSequential Organ Failure Assessment (SOFA) 序贯器官衰竭评估\nLactic acid/lactate 乳酸\ncreatinine 肌酐\nuric acid 尿酸\nserum creatinine 血清肌酐\namylase 淀粉酶\nlipase 脂肪酶\nBrain natriuretic peptide (BNP) 脑钠肽\nGlasgow /’ɡlɑ:sɡəu/ Coma /’kəʊmə/ Scale (GCS) 格拉斯哥昏迷评分\nAcute Physiology /,fɪzɪ’ɒlədʒɪ/ and Chronic Health Evaluation (APACHE) 急性生理慢性健康评分\nSimplified Acute Physiology Score (SAPS) 简化急性生理学评分\nCriteria /kraɪ’tɪərɪə/ 标准\nAKIN Criteria 急性肾损伤网络标准\nLactate clearance rate 乳酸清除率\nCentral venous pressure (CVP) 中心静脉压\nCerebral /səˈriːbrəl/ perfusion pressure (CPP) 脑灌注压\nSystemic vascular resistance (SVR) 体循环血管阻力\nPulmonary /ˈpʌlmənəri/ artery 肺动脉\nCoagulation profile 凝血功能检查\nFluid challenge 液体冲击试验\nMixed venous oxygen saturation (SvO₂) 混合静脉血氧饱和度\nOxygenation index 氧合指数\nPaO₂/FiO₂ 氧合指数\nEnd-Tidal Carbon Dioxide, ETCO₂ 呼气末二氧化碳\nNeurocritical care 神经重症监护\nCerebral Oxygen Monitoring 脑氧监测\nColony-Stimulating Factor, CSF 集落刺激因子\nIntestinal /ˌɪnˈtestɪnəl/ Barrier Function Monitoring 肠屏障功能监测\nContinuous EEG Monitoring 连续性神经电监测\nExtravascular Lung Water Index, EVLWI 血管外肺水指数\nCardiac index 心脏指数\nEnteral Nutrition Tolerance 肠内营养耐受评估\nSedation Depth Monitoring 镇静深度评估\nPain Assessment 疼痛评估"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#常用缩写",
    "href": "blog/learnnotes_words/index.html#常用缩写",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "1. hx - History（病史）\n2. dx - Diagnosis（诊断）\n3. tx - Treatment（治疗）\n4. sx - Symptoms（症状）\n5. fx - Fracture（骨折）\n6. px - Prognosis（预后）"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#科室",
    "href": "blog/learnnotes_words/index.html#科室",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Intensive Care Unit，ICU 重症监护室\nMultidisciplinary team (MDT) 多学科协作团队\nEnd-of-life care 临终关怀\nEthical decision-making 伦理决策\nEthics Committee Review 伦理委员会审查\nPatient autonomy /ɔːˈtɒnəmi/ 患者自主权\nFutility /fju:’tiliti/ of care 无效医疗\nDo-not-resuscitate (DNR) 放弃心肺复苏\nbrain death 脑死亡\nSurrogate /’sʌrəgət/ decision-making 替代决策\nPalliative /’pælɪətɪv/ care integration 姑息治疗整合\nEnd-of-life discussions 临终讨论\nTrauma team activation 创伤团队启动\nCardiac arrest team 心脏骤停团队\nTransplant ICU 抑制重症监护室\nNeurocritical care 神经重症"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#科研",
    "href": "blog/learnnotes_words/index.html#科研",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "Machine learning in sepsis prediction 机器学习在脓毒症预测中的应用\nGut Microbiota Modulation 肠道菌群调控\nGene Editing 基因编辑技术\nNanomedicine Delivery 纳米药物递送\nMetabolomics /metæˈbɑːləmɪks/ 代谢组学\nProteomics /ˌprəʊtɪˈɒmɪks/ 蛋白组学\nSingle-Cell Sequencing 单细胞测序"
  },
  {
    "objectID": "blog/learnnotes_words/index.html#基础单词",
    "href": "blog/learnnotes_words/index.html#基础单词",
    "title": "我的重症医学单词: 2025年8月27日",
    "section": "",
    "text": "deviate /ˈdiːvieɪt/ 偏离\noptimal 最优的\ncomply [kəmˈplaɪ] 遵从，服从\nfungal 真菌的\nregimen 方案、疗程\nanesthetic [ˌænəsˈθetɪk] 麻醉剂、麻醉的"
  },
  {
    "objectID": "blog/blog.html",
    "href": "blog/blog.html",
    "title": "笔记",
    "section": "",
    "text": "日志\n\n\n\n\n\n\nTitle\n\n\n\nDate\n\n\n\n\n\n\n\n\n面试——非专业问题\n\n\n11/5/24\n\n\n\n\n\n\nNo matching items\n\n\n\n学习笔记\n\n\n\n\n\n\nTitle\n\n\n\nDate\n\n\n\n\n\n\n\n\n我的重症医学单词: 2025年8月27日\n\n\n8/27/25\n\n\n\n\n\n\nNo matching items\n\n\n\n阅读\nThis section is constantly being updated.\n\n\n\n\n\n\nTitle\n\n\n\nDate\n\n\n\n\n\n\n\n\nBad Pharma: How medicine is broken, and how we can fix it - Ben Goldacre\n\n\n6/6/24\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "about_me.html",
    "href": "about_me.html",
    "title": "刘奥奇",
    "section": "",
    "text": "laqlkw@163.com\n  \n  \n    \n     laq12345\n  \n\n\n\n我很神秘，所以这里什么都没有\n如果想了解我，这里肯定是不行了\n不过不要难过，我依然爱着你，我的爱是平等而不匮乏的"
  },
  {
    "objectID": "blog/blog_interview_non_professional/index.html",
    "href": "blog/blog_interview_non_professional/index.html",
    "title": "面试——非专业问题",
    "section": "",
    "text": "1. 承认压力的普遍性，展现成熟心态\n\n“我认为在学习和科研中遇到压力是非常正常的，尤其是在面对重要任务、时间紧张或挑战性目标时。我不会回避压力，反而认为适度的压力是推动我成长和进步的动力。”\n\n2. 说明你如何识别和分析压力源（体现自我觉察）\n\n“当我感到压力时，我首先会停下来反思：压力来自哪里？是任务量太大？时间安排不合理？还是对结果的不确定性？明确压力源是解决问题的第一步。”\n\n3. 分享具体、有效的应对策略（重点！要具体）\n\n“针对不同的压力，我会采取不同的应对方式：\n\n时间管理：我会重新梳理任务优先级，使用待办清单或时间管理工具（如番茄工作法），把大任务拆解成小目标，一步步完成，避免拖延带来的累积压力。\n主动沟通：如果压力来自团队合作或导师期望，我会主动与同学或老师沟通，寻求建议或调整方案，而不是独自硬扛。\n调节身心：我也会通过运动（如跑步、跳绳）、听音乐或短暂冥想来放松大脑，保持清晰的思维。充足的睡眠和规律作息对我来说也很重要。\n积极心理暗示：我会提醒自己过去的成功经验，增强信心，告诉自己‘这个挑战我有能力应对。\n\n\n5. 总结升华\n\n“所以，我认为面对压力，关键不是逃避，而是理性分析、科学应对，并从中学习如何更好地管理自己。我相信这种能力也能帮助我在未来的研究生阶段应对更复杂的挑战。”\n\n\n\n\n\n\n\n\n“老师，我完全理解临床医学研究生，尤其是专硕阶段的工作确实非常辛苦——临床轮转任务重、科研压力大、节假日少，甚至经常需要熬夜值班。这些我都有心理准备，也认真了解过身边师兄师姐的经历。”\n\n\n“但我想说，’苦’是外在的体验，而我选择这条路，是因为我热爱医学、敬畏生命。在本科实习期间，看到老师和值班医生抢救病人，我深受触动。”\n\n\n“我也清楚，专硕阶段是临床能力打基础的关键时期。辛苦的背后，是大量动手操作的机会、是与患者直接沟通的成长、是逐步建立临床思维的过程。这些‘苦，在我看来是成长的必经之路，而不是单纯的消耗。”\n\n\n“当然，光有热情不够。我也在努力提升自己的抗压能力和时间管理能力。比如通过规律作息、阶段性复盘、与导师同学沟通协作等方式，让自己在高强度工作中保持效率和初心。”\n\n\n“所以，如果能有幸进入这里学习，我不仅‘能坚持’，更会主动适应、积极投入，把每一个挑战当作提升专业能力的机会。因为我始终记得自己学医的初心：治病救人，做一个有温度、有能力的医生。”\n\n\n\n\n\n\n\n\n\n“是的，我认为自己能够很好地融入团队，并为团队目标贡献力量。我始终相信，科研和临床工作都不是一个人的战斗，良好的团队协作是成功的关键。”\n\n\n“在本科期间，我参与过多个团队项目，比如全国大学生医学创新大赛。在项目中，我的主要工作是负责项目的单细胞数据分析流程和预测模型的构建，需要和不同背景的同学密切配合。我们定期开会沟通进度，遇到意见分歧时，我会主动倾听他人想法。\n\n\n“我也注重责任与沟通。比如在任务分工中，我会主动承担自己擅长的部分，同时也会关注队友的进度，如果发现有人遇到困难，我会主动提供帮助。我认为团队的成功比个人表现更重要。”\n\n\n“当然，我也意识到良好的相处不仅靠热情，更需要尊重、包容和有效沟通。我性格比较踏实、耐心，愿意倾听，也乐于分享自己的思路，这让我在团队中通常能建立信任关系。”\n\n\n“如果未来有幸进入贵校学习，我也希望能尽快融入课题组，和导师、师兄师姐、同门保持良好沟通，做一个靠谱、积极、有贡献的团队成员。”\n\n\n\n\n\n\n\n\n\n“老师，我认为挫折是成长过程中不可避免的一部分，尤其是在科研和学习中。面对挫折，我不会逃避，而是通过情绪调节、理性分析和行动调整三个步骤来逐步克服。”\n\n\n“比如在本科期间，我参与了一个国创项目，负责项目的单细胞数据分析流程的构建。但我最初对相关知识了解太少，也没有使用过Linux服务器，对这些新事物感到茫然。”\n\n\n“但我很快意识到，情绪解决不了问题。于是：\n\n我先调整心态：通过运动和与朋友倾诉释放压力，也提醒自己‘失败是科研常态’，避免陷入自我否定；\n我系统复盘：重新检查记录，反复练习基础操作；\n我主动求助：向导师和实验室的师兄请教；\n我调整方案：查找相关资料，更换更合适的方法。”\n\n\n\n“这次经历让我明白，挫折不是能力的否定，而是改进的信号。关键是要从‘情绪反应’转向‘问题解决’，把挫折当作一次系统性排查和提升的机会。”\n\n\n“所以，我克服挫折的方式不是靠‘硬扛’，而是：\n\n接纳情绪，但不被情绪主导\n拆解问题，找到根源\n主动沟通，借助外力\n迭代尝试，持续优化\n\n\n\n我相信，这种‘在失败中学习’的能力，正是研究生阶段最需要的素质之一。”"
  },
  {
    "objectID": "blog/blog_interview_non_professional/index.html#关于自己",
    "href": "blog/blog_interview_non_professional/index.html#关于自己",
    "title": "面试——非专业问题",
    "section": "",
    "text": "1. 承认压力的普遍性，展现成熟心态\n\n“我认为在学习和科研中遇到压力是非常正常的，尤其是在面对重要任务、时间紧张或挑战性目标时。我不会回避压力，反而认为适度的压力是推动我成长和进步的动力。”\n\n2. 说明你如何识别和分析压力源（体现自我觉察）\n\n“当我感到压力时，我首先会停下来反思：压力来自哪里？是任务量太大？时间安排不合理？还是对结果的不确定性？明确压力源是解决问题的第一步。”\n\n3. 分享具体、有效的应对策略（重点！要具体）\n\n“针对不同的压力，我会采取不同的应对方式：\n\n时间管理：我会重新梳理任务优先级，使用待办清单或时间管理工具（如番茄工作法），把大任务拆解成小目标，一步步完成，避免拖延带来的累积压力。\n主动沟通：如果压力来自团队合作或导师期望，我会主动与同学或老师沟通，寻求建议或调整方案，而不是独自硬扛。\n调节身心：我也会通过运动（如跑步、跳绳）、听音乐或短暂冥想来放松大脑，保持清晰的思维。充足的睡眠和规律作息对我来说也很重要。\n积极心理暗示：我会提醒自己过去的成功经验，增强信心，告诉自己‘这个挑战我有能力应对。\n\n\n5. 总结升华\n\n“所以，我认为面对压力，关键不是逃避，而是理性分析、科学应对，并从中学习如何更好地管理自己。我相信这种能力也能帮助我在未来的研究生阶段应对更复杂的挑战。”\n\n\n\n\n\n\n\n\n“老师，我完全理解临床医学研究生，尤其是专硕阶段的工作确实非常辛苦——临床轮转任务重、科研压力大、节假日少，甚至经常需要熬夜值班。这些我都有心理准备，也认真了解过身边师兄师姐的经历。”\n\n\n“但我想说，’苦’是外在的体验，而我选择这条路，是因为我热爱医学、敬畏生命。在本科实习期间，看到老师和值班医生抢救病人，我深受触动。”\n\n\n“我也清楚，专硕阶段是临床能力打基础的关键时期。辛苦的背后，是大量动手操作的机会、是与患者直接沟通的成长、是逐步建立临床思维的过程。这些‘苦，在我看来是成长的必经之路，而不是单纯的消耗。”\n\n\n“当然，光有热情不够。我也在努力提升自己的抗压能力和时间管理能力。比如通过规律作息、阶段性复盘、与导师同学沟通协作等方式，让自己在高强度工作中保持效率和初心。”\n\n\n“所以，如果能有幸进入这里学习，我不仅‘能坚持’，更会主动适应、积极投入，把每一个挑战当作提升专业能力的机会。因为我始终记得自己学医的初心：治病救人，做一个有温度、有能力的医生。”\n\n\n\n\n\n\n\n\n\n“是的，我认为自己能够很好地融入团队，并为团队目标贡献力量。我始终相信，科研和临床工作都不是一个人的战斗，良好的团队协作是成功的关键。”\n\n\n“在本科期间，我参与过多个团队项目，比如全国大学生医学创新大赛。在项目中，我的主要工作是负责项目的单细胞数据分析流程和预测模型的构建，需要和不同背景的同学密切配合。我们定期开会沟通进度，遇到意见分歧时，我会主动倾听他人想法。\n\n\n“我也注重责任与沟通。比如在任务分工中，我会主动承担自己擅长的部分，同时也会关注队友的进度，如果发现有人遇到困难，我会主动提供帮助。我认为团队的成功比个人表现更重要。”\n\n\n“当然，我也意识到良好的相处不仅靠热情，更需要尊重、包容和有效沟通。我性格比较踏实、耐心，愿意倾听，也乐于分享自己的思路，这让我在团队中通常能建立信任关系。”\n\n\n“如果未来有幸进入贵校学习，我也希望能尽快融入课题组，和导师、师兄师姐、同门保持良好沟通，做一个靠谱、积极、有贡献的团队成员。”\n\n\n\n\n\n\n\n\n\n“老师，我认为挫折是成长过程中不可避免的一部分，尤其是在科研和学习中。面对挫折，我不会逃避，而是通过情绪调节、理性分析和行动调整三个步骤来逐步克服。”\n\n\n“比如在本科期间，我参与了一个国创项目，负责项目的单细胞数据分析流程的构建。但我最初对相关知识了解太少，也没有使用过Linux服务器，对这些新事物感到茫然。”\n\n\n“但我很快意识到，情绪解决不了问题。于是：\n\n我先调整心态：通过运动和与朋友倾诉释放压力，也提醒自己‘失败是科研常态’，避免陷入自我否定；\n我系统复盘：重新检查记录，反复练习基础操作；\n我主动求助：向导师和实验室的师兄请教；\n我调整方案：查找相关资料，更换更合适的方法。”\n\n\n\n“这次经历让我明白，挫折不是能力的否定，而是改进的信号。关键是要从‘情绪反应’转向‘问题解决’，把挫折当作一次系统性排查和提升的机会。”\n\n\n“所以，我克服挫折的方式不是靠‘硬扛’，而是：\n\n接纳情绪，但不被情绪主导\n拆解问题，找到根源\n主动沟通，借助外力\n迭代尝试，持续优化\n\n\n\n我相信，这种‘在失败中学习’的能力，正是研究生阶段最需要的素质之一。”"
  },
  {
    "objectID": "blog/readnotes_20240606_bad_pharma/index.html",
    "href": "blog/readnotes_20240606_bad_pharma/index.html",
    "title": "Bad Pharma: How medicine is broken, and how we can fix it - Ben Goldacre",
    "section": "",
    "text": "Industry funded trials were twenty times more likely to give results that are favoring the test drug\n\nOn the need for meta-analysis\n\nPeople would write long review articles surveying the literature - in which they would cite the trial data they come across in a completely unsystematic fashion, often reflecting their own prejudice and values.\n\nOn trials\n\n… mild torture economy: you’re not being paid to do a job, you’re being paid to endure.\n\nOn regulators\n\nfree movement of staff between regulators and drug companies… a fifth of those surveyed said they had been pressured to approve a drug despite reservation about efficacy and safety\n\n\napplication from large companies, which have greater experience with the regulatory process, pass through to approval faster than those from smaller companies\n\nOn surrogate outcomes\n\nthey are approved for showing a benefit on surrogate outcomes, such as blood test, that is only weakly or theoretically associated with the real suffering and death we’re trying to avoid. Sometimes drugs which work well to change surrogate outcomes simply don’t make any difference to the real outcome.\n\nOn comparative effectiveness research\n\nit is a vitally important filed, in many cases the value of finding out what works best among the drugs we already have would hugely exceed the value of developing entirely new ones.\n\nOn safety and efficacy for approved drugs\n\n39 percent patients believe that FDA only approves ‘extremely effective’ drugs, and 25 percent that it only approves drugs without serious side effect. However regulators frequently approve drugs that are only vaguely effective, with serious side effects, on the off-chance that they might be useful to someone, somewhere, when other interventions aren’t an option.\n\nOn drug reviewing\n\nRegulators that have approved a drug are often reluctant to take it off the market, in case it is seen as an admissio of their failure to spot problems in the first place\n\nOn trial patients\n\nthe ‘ideal’ patients are likely to get better, they exaggerate the benefits of drugs, and help expensive new medicines appear to be more cost effective than they really are. ‘External validity’: trial patient being unrepresentative\n\nOn comparison drugs\n\nit is common to see trials where a new drug is compared to a competitor that is known to be useless; or with a good competitor at a stupidly low (or high) dose\n\nOn random variation in the data\n\nearly stopping because you peeked in the results. should set up stopping rules, specified before the trial begins\nneed a large trial to detect a small difference between two treatments, and a very large trial to be confident that two drugs are equally effective\n(multiple testing, sub-group analysis): measuring lots of things, some will be statistically significant, simply from the natural random variation in all trial data.\n\nOn presenting the results\n\npercent reduction in the risk of heart attack (risk difference)\nrelative risk reduction\npresenting the results as relative risk reduction overstates the benefits\n\nWays trials go wrong\n\nunrepresentative patients\ntoo brief\nmeasure the wrong outcomes\ngo missing, if the result is unflattering\nanalysed wrongly\n\nOn ‘simple trial’ using EHR\n\nat present trials are very expensive. Many struggle to recruit enough patients, many struggle to recruit everyday doctors who don’t want to get involved in the mess of filing out patient report forms, calling patients back for extra appointments, doing extra measurements and so on\nsimple trials have disadvantage of being not blinded - patients know what drug they’ve received\npragmatic trials are cheap\nthese trials run forever and follow-up data are easy to get\n\nOn marketing\n\nSome have estimated that the pharmaceutical industry overall spends twice as much on marketing and promotion as it does on research and developments\n\n\nDrugs are advertised more when the number of potential patients, rather than the current patients, is large."
  },
  {
    "objectID": "blog/readnotes_20240606_bad_pharma/index.html#notes-from-the-book",
    "href": "blog/readnotes_20240606_bad_pharma/index.html#notes-from-the-book",
    "title": "Bad Pharma: How medicine is broken, and how we can fix it - Ben Goldacre",
    "section": "",
    "text": "Industry funded trials were twenty times more likely to give results that are favoring the test drug\n\nOn the need for meta-analysis\n\nPeople would write long review articles surveying the literature - in which they would cite the trial data they come across in a completely unsystematic fashion, often reflecting their own prejudice and values.\n\nOn trials\n\n… mild torture economy: you’re not being paid to do a job, you’re being paid to endure.\n\nOn regulators\n\nfree movement of staff between regulators and drug companies… a fifth of those surveyed said they had been pressured to approve a drug despite reservation about efficacy and safety\n\n\napplication from large companies, which have greater experience with the regulatory process, pass through to approval faster than those from smaller companies\n\nOn surrogate outcomes\n\nthey are approved for showing a benefit on surrogate outcomes, such as blood test, that is only weakly or theoretically associated with the real suffering and death we’re trying to avoid. Sometimes drugs which work well to change surrogate outcomes simply don’t make any difference to the real outcome.\n\nOn comparative effectiveness research\n\nit is a vitally important filed, in many cases the value of finding out what works best among the drugs we already have would hugely exceed the value of developing entirely new ones.\n\nOn safety and efficacy for approved drugs\n\n39 percent patients believe that FDA only approves ‘extremely effective’ drugs, and 25 percent that it only approves drugs without serious side effect. However regulators frequently approve drugs that are only vaguely effective, with serious side effects, on the off-chance that they might be useful to someone, somewhere, when other interventions aren’t an option.\n\nOn drug reviewing\n\nRegulators that have approved a drug are often reluctant to take it off the market, in case it is seen as an admissio of their failure to spot problems in the first place\n\nOn trial patients\n\nthe ‘ideal’ patients are likely to get better, they exaggerate the benefits of drugs, and help expensive new medicines appear to be more cost effective than they really are. ‘External validity’: trial patient being unrepresentative\n\nOn comparison drugs\n\nit is common to see trials where a new drug is compared to a competitor that is known to be useless; or with a good competitor at a stupidly low (or high) dose\n\nOn random variation in the data\n\nearly stopping because you peeked in the results. should set up stopping rules, specified before the trial begins\nneed a large trial to detect a small difference between two treatments, and a very large trial to be confident that two drugs are equally effective\n(multiple testing, sub-group analysis): measuring lots of things, some will be statistically significant, simply from the natural random variation in all trial data.\n\nOn presenting the results\n\npercent reduction in the risk of heart attack (risk difference)\nrelative risk reduction\npresenting the results as relative risk reduction overstates the benefits\n\nWays trials go wrong\n\nunrepresentative patients\ntoo brief\nmeasure the wrong outcomes\ngo missing, if the result is unflattering\nanalysed wrongly\n\nOn ‘simple trial’ using EHR\n\nat present trials are very expensive. Many struggle to recruit enough patients, many struggle to recruit everyday doctors who don’t want to get involved in the mess of filing out patient report forms, calling patients back for extra appointments, doing extra measurements and so on\nsimple trials have disadvantage of being not blinded - patients know what drug they’ve received\npragmatic trials are cheap\nthese trials run forever and follow-up data are easy to get\n\nOn marketing\n\nSome have estimated that the pharmaceutical industry overall spends twice as much on marketing and promotion as it does on research and developments\n\n\nDrugs are advertised more when the number of potential patients, rather than the current patients, is large."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "刘奥奇",
    "section": "",
    "text": "laqlkw@163.com\n  \n  \n    \n     laq12345\n  \n\n  \n  \n欢迎来到我的个人主页。我的主页很无聊，随意看看吧！"
  },
  {
    "objectID": "projects/dan/index.html",
    "href": "projects/dan/index.html",
    "title": "Data Apothecary’s Notes",
    "section": "",
    "text": "(This is my own note-taking system using quarto)\n\nAbout the notes\nData Apothecary’s Notes is a note-taking repository for modern data science skills with a focus on drug development and clinical trials. Content will be gradually added while I learn the topics. Therefore, it is by no means a complete guide by the time you read it!\nI try to organize the content in a modular way. I think these should cover the important aspects in which a data scientist / modern statistician should know.\n\nstudy design\ninference\nmodels\nreporting\nprogramming\n\n\n\nWhy quarto\nIn short, quarto has the advantage of making a very well structured website with code chunks easy. No more worry about scattered notes in different folders - put them together, render it so you can find your notes quickly!"
  },
  {
    "objectID": "projects/noreden/index.html",
    "href": "projects/noreden/index.html",
    "title": "Noreden",
    "section": "",
    "text": "Noreden"
  },
  {
    "objectID": "projects/os_teaching/index.html",
    "href": "projects/os_teaching/index.html",
    "title": "Teach in R and Quarto",
    "section": "",
    "text": "MF9130E - Introductory course in statistics\n8-day intensive course on introductory statistics. April 2023 we made it with R rather than propriety software, coupled with live-coding sessions to enhance understanding of basic concepts such as distribution and hypothesis tests.\nRepository\nCourse website\nRead more about the experience in\n\nblogpost\npresentation"
  },
  {
    "objectID": "projects/projects.html",
    "href": "projects/projects.html",
    "title": "Projects",
    "section": "",
    "text": "Real World Data and Public health\nMy main research interest is hospital Electronic Health Records and large health registry data. My PhD (completed in 2022) focused on representation and utilization of hospital EHR data. I am currently working on quality assurance of the prescription and use of antibiotics in a hospital setting, and an R package ggehr to facilitate the exploration of EHR data.\nIn 2020-2022, I worked at Norwegian Institute of Public Health during Covid-19 pandemic. I helped develop Sykdomspulsen (now CSIDS), a real-time infectious disease surveillance and real-time large scale reporting with open source technology.\nSince 2023, I joined NOR-Eden and Norkost projects at University of Oslo. I help develop a set of R tools to facilitate sustainable diet design, noreden.\n\n\n\n\n\n\n\n\n\n\nggehr\n\n\nggplot2 extension to EHR data\n\n\n\n\n\n\n\n\n\n\n\n\nCSIDS\n\n\nConsortium for Statistics in Disease Surveillance\n\n\n\n\n\nNo matching items\n\n\n\nOpen source data science in healthcare\nI work on open source data science projects with healthcare applications. I am the developer of MF9310E quarto website, leading the transition of teaching university biostatistics courses using R and Quarto. I’m also a co-lead of the PHUSE CAMIS project.\n\n\n\n\n\n\n\n\n\n\nTeach in R and Quarto\n\n\nTransform biostatistics classroom into R and quarto\n\n\n\n\n\n\n\n\n\n\n\n\nPHUSE - CAMIS\n\n\nContributor to the Global Healthcare Data Science Community\n\n\n\n\n\n\n\n\n\n\n\n\nData Apothecary’s Notes\n\n\nMy own note-taking system for a modern health data scientist\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "research/cheatsheet_pkgdev/index.html",
    "href": "research/cheatsheet_pkgdev/index.html",
    "title": "Pkg Dev at CSIDS",
    "section": "",
    "text": "Rstat"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html",
    "href": "research/literature_chengyisong_20240215/index.html",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "脓毒症是全球第三大死因，抗生素治疗对改善预后至关重要。\n当前抗生素的使用依赖医生经验，容易导致用药不足或过度，增加耐药风险。\n尽管强化学习（RL）已被用于脓毒症的液体复苏、升压药等治疗决策，但尚无研究将其用于抗生素组合和疗程的推荐。\n现有AI模型缺乏与临床知识的融合，可能导致决策偏离医学常识。\n\n\n\n\n开发一个个性化、可解释、符合临床指南的抗生素用药推荐系统，解决：\n\n何时开始和停止抗生素？\n选择哪种抗生素组合？\n如何平衡疗效与用药时长？\n\n\n\n\n提出 Sepsis Anti-infection Deep Q-Network (SAI-DQN) 模型，基于深度Q网络（DQN）框架，将治疗过程建模为马尔可夫决策过程（MDP）。\n\n\n\n状态空间（State Space）：\n\n包括患者的人口统计学特征、37项实验室指标、15项生命体征。\n特别纳入微生物培养结果（共2047种细菌-抗生素敏感性组合），形成高维稀疏输入。\n\n动作空间（Action Space）：\n\n动作为每日的抗生素组合选择。\n使用K-means聚类将历史用药序列聚为30类，作为可选动作。\n\n数据来源：\n\n主数据集：MIMIC-IV（9982名脓毒症患者）。\n外部验证集：eICU 数据库（11,070名患者）。\n\n缺失值处理：\n\n采用混合插补法（前向填充 + K近邻），兼顾个体趋势与临床合理性。\n\n\n\n\n\n设计了四个奖励函数，将医学知识融入强化学习训练过程，提升模型的可解释性和临床一致性：\n\n\n\n\n\n\n\n\n奖励函数\n设计目的\n具体设置\n\n\n\n\nR1\n学习患者长期预后\n90天存活：+100；死亡：-100\n\n\nR2\n鼓励改善病情\nSOFA评分下降：+10；上升：-10\n\n\nR3\n缩短抗生素使用时间\n用药 &gt;9天：-10（鼓励合理缩短疗程）\n\n\nR4\n融合真实临床用药模式\n基于真实数据状态转移的Q值 × 0.1\n\n\n\n\n✅ 这是首次在脓毒症抗生素推荐中引入“用药时长”作为优化目标之一。\n\n\n\n\n\n\n模型性能评估：\n\n使用加权重要性采样（WIS） 评估策略价值，SAI-DQN 的决策价值显著高于临床实际决策。\n\n预测效果：\n\n在测试集中，模型推荐的抗生素组合可使 79.07% 的患者获得良好预后。\n\n可解释性分析：\n\n模型推荐的用药路径符合临床实践，能根据患者状态动态调整。\n例如：在感染未控制时持续用药，在病情好转后及时停药。\n\n\n\n\n\n\n首次将深度强化学习应用于脓毒症抗生素组合推荐。\n首次关注抗生素“使用时长”问题，通过奖励函数鼓励合理缩短疗程，减少滥用。\n将临床指南和医学知识融入奖励函数，提升模型的可解释性和临床一致性。\n整合微生物培养数据，实现更精准的个体化推荐。\n\n\n\n\nSAI-DQN 模型能够：\n\n生成符合临床知识的个性化抗生素用药方案；\n在提升患者预后的同时，减少不必要的长期用药；\n为临床医生提供可解释的决策支持工具，助力抗感染治疗的精准化。\n\n\n\n该研究为AI在复杂临床决策中的应用提供了新范式——不仅仅是“预测最佳动作”，更要“符合医学逻辑”。未来可扩展至其他多药联合治疗场景，推动AI从“黑箱”走向“白箱”医疗决策。"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#背景",
    "href": "research/literature_chengyisong_20240215/index.html#背景",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "脓毒症是全球第三大死因，抗生素治疗对改善预后至关重要。\n当前抗生素的使用依赖医生经验，容易导致用药不足或过度，增加耐药风险。\n尽管强化学习（RL）已被用于脓毒症的液体复苏、升压药等治疗决策，但尚无研究将其用于抗生素组合和疗程的推荐。\n现有AI模型缺乏与临床知识的融合，可能导致决策偏离医学常识。"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#研究目标",
    "href": "research/literature_chengyisong_20240215/index.html#研究目标",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "开发一个个性化、可解释、符合临床指南的抗生素用药推荐系统，解决：\n\n何时开始和停止抗生素？\n选择哪种抗生素组合？\n如何平衡疗效与用药时长？"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#方法sai-dqn-模型",
    "href": "research/literature_chengyisong_20240215/index.html#方法sai-dqn-模型",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "提出 Sepsis Anti-infection Deep Q-Network (SAI-DQN) 模型，基于深度Q网络（DQN）框架，将治疗过程建模为马尔可夫决策过程（MDP）。\n\n\n\n状态空间（State Space）：\n\n包括患者的人口统计学特征、37项实验室指标、15项生命体征。\n特别纳入微生物培养结果（共2047种细菌-抗生素敏感性组合），形成高维稀疏输入。\n\n动作空间（Action Space）：\n\n动作为每日的抗生素组合选择。\n使用K-means聚类将历史用药序列聚为30类，作为可选动作。\n\n数据来源：\n\n主数据集：MIMIC-IV（9982名脓毒症患者）。\n外部验证集：eICU 数据库（11,070名患者）。\n\n缺失值处理：\n\n采用混合插补法（前向填充 + K近邻），兼顾个体趋势与临床合理性。\n\n\n\n\n\n设计了四个奖励函数，将医学知识融入强化学习训练过程，提升模型的可解释性和临床一致性：\n\n\n\n\n\n\n\n\n奖励函数\n设计目的\n具体设置\n\n\n\n\nR1\n学习患者长期预后\n90天存活：+100；死亡：-100\n\n\nR2\n鼓励改善病情\nSOFA评分下降：+10；上升：-10\n\n\nR3\n缩短抗生素使用时间\n用药 &gt;9天：-10（鼓励合理缩短疗程）\n\n\nR4\n融合真实临床用药模式\n基于真实数据状态转移的Q值 × 0.1\n\n\n\n\n✅ 这是首次在脓毒症抗生素推荐中引入“用药时长”作为优化目标之一。"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#实验结果",
    "href": "research/literature_chengyisong_20240215/index.html#实验结果",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "模型性能评估：\n\n使用加权重要性采样（WIS） 评估策略价值，SAI-DQN 的决策价值显著高于临床实际决策。\n\n预测效果：\n\n在测试集中，模型推荐的抗生素组合可使 79.07% 的患者获得良好预后。\n\n可解释性分析：\n\n模型推荐的用药路径符合临床实践，能根据患者状态动态调整。\n例如：在感染未控制时持续用药，在病情好转后及时停药。"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#主要贡献",
    "href": "research/literature_chengyisong_20240215/index.html#主要贡献",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "首次将深度强化学习应用于脓毒症抗生素组合推荐。\n首次关注抗生素“使用时长”问题，通过奖励函数鼓励合理缩短疗程，减少滥用。\n将临床指南和医学知识融入奖励函数，提升模型的可解释性和临床一致性。\n整合微生物培养数据，实现更精准的个体化推荐。"
  },
  {
    "objectID": "research/literature_chengyisong_20240215/index.html#结论",
    "href": "research/literature_chengyisong_20240215/index.html#结论",
    "title": "Clinical knowledge-guided deep reinforcement learning for sepsis antibiotic dosing recommendations",
    "section": "",
    "text": "SAI-DQN 模型能够：\n\n生成符合临床知识的个性化抗生素用药方案；\n在提升患者预后的同时，减少不必要的长期用药；\n为临床医生提供可解释的决策支持工具，助力抗感染治疗的精准化。\n\n\n\n该研究为AI在复杂临床决策中的应用提供了新范式——不仅仅是“预测最佳动作”，更要“符合医学逻辑”。未来可扩展至其他多药联合治疗场景，推动AI从“黑箱”走向“白箱”医疗决策。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html",
    "href": "research/literature_kangyan_20250703/index.html",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "机械通气的挑战\n\n机械通气是治疗呼吸衰竭的关键手段，但辅助过度可能导致呼吸机诱导的膈肌功能障碍（Ventilator-Induced Diaphragm Dysfunction, VIDD），辅助不足引起膈肌过度用力损伤。\n过强通气：过度辅助导致膈肌萎缩和无力；过弱通气：患者需过度努力呼吸，引发肺部高应激、肺泡过度扩张或异步性呼吸。\n\n现有监测方法的局限性\n\n直接方法：如食管压（Pes）、跨膈压（Pdi）需侵入性操作，存在操作风险，操作复杂。\n间接方法：如呼气末阻断法（PMI）、膈肌超声等依赖专业人员操作，且在复杂病理状态下（如ARDS、COPD）准确性受限。\n需求：开发一种非侵入性、实时、床旁可用的呼吸努力监测技术（N-Pmus），以优化机械通气参数，预防肺和膈肌损伤。\n\n\n\n\n\n\n\n1. 算法开发：基于呼吸系统运动方程，构建无创实时呼吸肌压力监测算法（N-Pmus），通过生理合理的三次多项式函数建模呼吸肌压力（Pmus）波形，减少未知变量，采用迭代最小二乘法求解超定方程组。 2. 实验设置：使用 ASL5000 呼吸模拟器与 SV800 呼吸机，模拟 3 类临床场景（正常、限制性、阻塞性），涵盖不同呼吸肌压力强度（3-30 cmH₂O）、上升/释放相位，共 270 个场景，对比 N-Pmus 与 ASL5000 设定的 Pmus（ASL5000-Pmus）。\n\n\n\n1. 研究设计：单中心前瞻性观察研究，于 2023 年在四川大学华西医院 ICU 开展，纳入 23 例机械通气患者（8 例 ARDS、8 例 COPD、7 例其他呼吸衰竭）。 2. 监测与对比：患者经鼻插入食道气囊导管监测食道压，计算食道压衍生的 Pmus（Pmusₑₛₒ），同时记录 N-Pmus，对比二者相关性与一致性；此外还分析呼吸肌压力时间乘积（N-PTPmus 与 PTPmusₑₛₒ）的关联。 3. 统计方法：采用线性混合效应模型分析相关性（计算边际 R² 和条件 R²），通过 Bland-Altman 分析评估一致性（计算偏差与 95%一致性界限）， subgroups 分析涵盖疾病类型、通气模式、呼吸努力强度。\n\n\n\n\n\n\nN-Pmus 与 ASL5000-Pmus 相关性极高：\n\n边际 R²=0.993，条件 R²=0.997；\n偏差为-0.23 cmH₂O，95%一致性界限为-1.51 至 1.04 cmH₂O；\n限制性、阻塞性亚组均保持高相关性（边际 R²&gt;0.988，条件 R²&gt;0.992）。\n\n\n\n\n\nN-Pmus 与 Pmusₑₛₒ 对比\n\n聚合数据（每患者 2-4 个稳定呼吸段，每段 20 个呼吸周期）：边际 R²=0.97，条件 R²=0.971，偏差-0.2 cmH₂O，95%一致性界限-2.22 至 1.83 cmH₂O；\n单周期数据：边际 R²=0.884，条件 R²=0.952，偏差-0.23 cmH₂O，95%一致性界限-2.33 至 1.88 cmH₂O。\n\nN-PTPmus 与 PTPmusₑₛₒ 对比：边际 R²=0.861，条件 R²=0.907，偏差-0.18 cmH₂O·s，95%一致性界限-2.45 至 2.08 cmH₂O·s。\n亚组分析结果\n\n疾病类型：ARDS 亚组相关性最高（边际 R²=0.955），COPD 亚组（边际 R²=0.822）、其他疾病亚组（边际 R²=0.876）稍低；\n通气模式：容量辅助控制通气（V-A/C）相关性最高（边际 R²=0.978），压力辅助控制（P-A/C）、压力支持（PSV）、同步间歇指令通气（SIMV）均保持良好一致性；\n呼吸努力强度：高努力组（Pmusₑₛₒ&gt;10 cmH₂O）相关性最高（边际 R²=0.895），低努力组（&lt;4 cmH₂O，边际 R²=0.611）、正常努力组（4-10 cmH₂O，边际 R²=0.628）稍低。\n\n\n\n\n\n\n1. 核心结论：N-Pmus 作为新型无创实时呼吸努力监测方法，与模拟实验金标准（ASL5000-Pmus）及临床金标准（Pmusₑₛₒ）均具有高相关性与良好一致性，且在不同疾病类型、通气模式、呼吸努力强度下均稳定有效。\n2. 临床意义：解决了现有监测方法的有创性、复杂性问题，可实现床旁实时监测，为机械通气参数精准调整提供依据，有望减少呼吸机相关肺损伤（P-SILI）与膈肌功能障碍（VIDD），改善患者预后。\n\n\n\n1. 食道压虽为胸膜压的近似指标，但在某些病理状态下可能无法完全反映真实胸腔内压力，且胸壁顺应性可能受通气模式影响；\n2. 研究为单中心、小样本（23 例）、短期观察，缺乏健康人群及特殊人群（如腹腔高压）数据；\n3. 未评估跨膈肌压力（Pdi），需后续多中心、大样本、长期研究进一步验证。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html#背景",
    "href": "research/literature_kangyan_20250703/index.html#背景",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "机械通气的挑战\n\n机械通气是治疗呼吸衰竭的关键手段，但辅助过度可能导致呼吸机诱导的膈肌功能障碍（Ventilator-Induced Diaphragm Dysfunction, VIDD），辅助不足引起膈肌过度用力损伤。\n过强通气：过度辅助导致膈肌萎缩和无力；过弱通气：患者需过度努力呼吸，引发肺部高应激、肺泡过度扩张或异步性呼吸。\n\n现有监测方法的局限性\n\n直接方法：如食管压（Pes）、跨膈压（Pdi）需侵入性操作，存在操作风险，操作复杂。\n间接方法：如呼气末阻断法（PMI）、膈肌超声等依赖专业人员操作，且在复杂病理状态下（如ARDS、COPD）准确性受限。\n需求：开发一种非侵入性、实时、床旁可用的呼吸努力监测技术（N-Pmus），以优化机械通气参数，预防肺和膈肌损伤。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html#方法",
    "href": "research/literature_kangyan_20250703/index.html#方法",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "1. 算法开发：基于呼吸系统运动方程，构建无创实时呼吸肌压力监测算法（N-Pmus），通过生理合理的三次多项式函数建模呼吸肌压力（Pmus）波形，减少未知变量，采用迭代最小二乘法求解超定方程组。 2. 实验设置：使用 ASL5000 呼吸模拟器与 SV800 呼吸机，模拟 3 类临床场景（正常、限制性、阻塞性），涵盖不同呼吸肌压力强度（3-30 cmH₂O）、上升/释放相位，共 270 个场景，对比 N-Pmus 与 ASL5000 设定的 Pmus（ASL5000-Pmus）。\n\n\n\n1. 研究设计：单中心前瞻性观察研究，于 2023 年在四川大学华西医院 ICU 开展，纳入 23 例机械通气患者（8 例 ARDS、8 例 COPD、7 例其他呼吸衰竭）。 2. 监测与对比：患者经鼻插入食道气囊导管监测食道压，计算食道压衍生的 Pmus（Pmusₑₛₒ），同时记录 N-Pmus，对比二者相关性与一致性；此外还分析呼吸肌压力时间乘积（N-PTPmus 与 PTPmusₑₛₒ）的关联。 3. 统计方法：采用线性混合效应模型分析相关性（计算边际 R² 和条件 R²），通过 Bland-Altman 分析评估一致性（计算偏差与 95%一致性界限）， subgroups 分析涵盖疾病类型、通气模式、呼吸努力强度。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html#结果",
    "href": "research/literature_kangyan_20250703/index.html#结果",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "N-Pmus 与 ASL5000-Pmus 相关性极高：\n\n边际 R²=0.993，条件 R²=0.997；\n偏差为-0.23 cmH₂O，95%一致性界限为-1.51 至 1.04 cmH₂O；\n限制性、阻塞性亚组均保持高相关性（边际 R²&gt;0.988，条件 R²&gt;0.992）。\n\n\n\n\n\nN-Pmus 与 Pmusₑₛₒ 对比\n\n聚合数据（每患者 2-4 个稳定呼吸段，每段 20 个呼吸周期）：边际 R²=0.97，条件 R²=0.971，偏差-0.2 cmH₂O，95%一致性界限-2.22 至 1.83 cmH₂O；\n单周期数据：边际 R²=0.884，条件 R²=0.952，偏差-0.23 cmH₂O，95%一致性界限-2.33 至 1.88 cmH₂O。\n\nN-PTPmus 与 PTPmusₑₛₒ 对比：边际 R²=0.861，条件 R²=0.907，偏差-0.18 cmH₂O·s，95%一致性界限-2.45 至 2.08 cmH₂O·s。\n亚组分析结果\n\n疾病类型：ARDS 亚组相关性最高（边际 R²=0.955），COPD 亚组（边际 R²=0.822）、其他疾病亚组（边际 R²=0.876）稍低；\n通气模式：容量辅助控制通气（V-A/C）相关性最高（边际 R²=0.978），压力辅助控制（P-A/C）、压力支持（PSV）、同步间歇指令通气（SIMV）均保持良好一致性；\n呼吸努力强度：高努力组（Pmusₑₛₒ&gt;10 cmH₂O）相关性最高（边际 R²=0.895），低努力组（&lt;4 cmH₂O，边际 R²=0.611）、正常努力组（4-10 cmH₂O，边际 R²=0.628）稍低。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html#结论与意义",
    "href": "research/literature_kangyan_20250703/index.html#结论与意义",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "1. 核心结论：N-Pmus 作为新型无创实时呼吸努力监测方法，与模拟实验金标准（ASL5000-Pmus）及临床金标准（Pmusₑₛₒ）均具有高相关性与良好一致性，且在不同疾病类型、通气模式、呼吸努力强度下均稳定有效。\n2. 临床意义：解决了现有监测方法的有创性、复杂性问题，可实现床旁实时监测，为机械通气参数精准调整提供依据，有望减少呼吸机相关肺损伤（P-SILI）与膈肌功能障碍（VIDD），改善患者预后。"
  },
  {
    "objectID": "research/literature_kangyan_20250703/index.html#局限性",
    "href": "research/literature_kangyan_20250703/index.html#局限性",
    "title": "Respiratory effort monitoring: a novel, bedside, non-invasive, real-time method.",
    "section": "",
    "text": "1. 食道压虽为胸膜压的近似指标，但在某些病理状态下可能无法完全反映真实胸腔内压力，且胸壁顺应性可能受通气模式影响；\n2. 研究为单中心、小样本（23 例）、短期观察，缺乏健康人群及特殊人群（如腹腔高压）数据；\n3. 未评估跨膈肌压力（Pdi），需后续多中心、大样本、长期研究进一步验证。"
  },
  {
    "objectID": "research/workshop_singlecell/index.html",
    "href": "research/workshop_singlecell/index.html",
    "title": "单细胞测序",
    "section": "",
    "text": "什么是单细胞测序技术？\n\n\n\n\n\n\n单细胞测序\n\n\n\n单细胞测序（Single-cell sequencing）是一种在单个细胞水平解析基因组、转录组等遗传信息的高通量测序技术。其核心目标是突破传统测序对细胞群体“平均化分析”的局限，揭示细胞间的异质性（如基因表达差异、功能状态、稀有细胞亚群等），从而更精准地理解生命活动机制和疾病进程。\n\n\n\n\n\n\n\n\n核心价值\n\n\n\n\n精准识别稀有细胞亚群（如肿瘤干细胞、免疫记忆细胞）。\n解析细胞分化轨迹（如胚胎发育、干细胞分化）。\n揭示疾病中的细胞异质性演化规律（如肿瘤微环境、免疫逃逸）。\n多组学整合分析（如转录组+表观组+蛋白组）。\n\n\n\n\n\n\n技术原理与关键环节\n\n1. 核心原理\n\n单细胞分离：将单个细胞从群体中分离，避免混合样本的平均效应。\n核酸扩增：因单细胞内DNA/RNA含量极低（皮克级），需通过全基因组扩增（WGA）或全转录组扩增（WTA）放大信号。\n文库构建与测序：将扩增产物转化为测序文库，利用高通量测序平台（如Illumina）获取数据。\n数据分析：通过生物信息学工具解析基因表达谱、细胞类型分类、功能注释等。\n\n\n\n2. 关键技术环节\n\n单细胞分离技术核酸扩增技术多组学整合\n\n\n\n显微操作法：精度高但通量低，适用于少量样本。\n流式细胞分选：基于荧光标记自动化分选，通量较高但依赖细胞状态。\n微流控芯片（主流）：利用微通道设计实现高通量、低损伤捕获（如10x Genomics Chromium系统）。\n\n\n\n\nPCR-based方法：操作简便但存在扩增偏倚。\nMDA（多重置换扩增）：覆盖度较好但一致性差。\nMALBAC（多重退火环状循环扩增）：由谢晓亮团队开发，通过环化引物降低扩增偏倚，覆盖93%的基因组，适用于检测单细胞序列变异。\n\n\n\n\n单细胞ATAC-seq：研究染色质开放性。\n表面蛋白检测：结合Feature Barcode技术（如10x Genomics）或抗体标记（如BioLegend）。\n空间转录组：如华大Stereo-cell技术，通过DNA纳米球阵列实现原位空间定位。\n\n\n\n\n\n\n\n\n实验流程\n\n样本制备：\n\n实体组织需解离为单细胞悬液（酶解或机械研磨），需优化方案以保持细胞活性。\n样品要求：细胞活率&gt;80%，浓度7×10⁵-1.2×10⁶ cells/mL，直径&lt;40μm。\n\n单细胞捕获：\n\n使用微流控芯片或微孔板技术（如10x Genomics）捕获单细胞。\n\n核酸扩增：\n\n通过GemCode技术（10x Genomics）或MALBAC技术扩增DNA/RNA。\n\n文库构建与测序：\n\n将扩增产物构建为测序文库，结合Illumina等平台进行高通量测序。\n\n数据分析：\n\n使用工具如Seurat、Scanpy进行聚类、差异基因分析、轨迹推断（如Pseudotime分析）。\n整合多组学数据（如转录组+ATAC-seq）解析调控网络。\n\n\n\n\n\n单细胞测序关键技术与方法\n\n单细胞转录组扩增技术：\n\nSmart-seq：一种全转录组扩增（WTA）方法，通过oligo-dT引物和模板转换实现全长cDNA扩增。\nSmart-seq2：改进版，提供更稳定和准确的mRNA测量。\nQuartz-Seq：通过poly(A)标记实现高灵敏度的转录组扩增。\nCEL-seq：基于体外转录的WTA方法。\nRamDa-seq：能够检测单细胞中的非poly(A)转录本，包括长非编码RNA和增强子RNA。\n\n微滴技术和微孔技术：\n\nDrop-Seq：基于微滴技术，将单个细胞/核、反应液和条形码珠子封装在油滴中，通过分子/细胞条形码进行逆转录（RT）。\nDroNc-seq：类似Drop-Seq，但专门用于单核RNA-seq。\nMicrowell-seq：基于微孔技术，将单个细胞和条形码珠子隔离在微孔中。\nNx1-seq 和 Seq-Well：便携式、低成本的微孔平台，适用于高通量单细胞分析。\n\n高通量和低成本方法：\n\nsci-RNA-seq：组合索引方法，最新版本为sci-RNA-seq3，适用于大规模单细胞分析。\n自动平台：如C1 Single-Cell Auto Prep系统（Fluidigm），可自动完成细胞分离、细胞裂解、RT和PCR扩增。\n\n测序平台：\n\n基于微滴技术：Chromium（10× Genomics）、ddSEQ（Bio-Rad/Illumina）、Nadia（Dolomite）、inDrop（1CellBio）。\n基于微孔技术：Rhapsody（BD）、ICELL8（Takara）。\n\n\n\n\n\nC1/Smart-seq平台适用于需要深入转录组信息的研究，而Chromium平台适用于高通量分析\n\n\n\nSeurat：一个综合性的R包\n\n数据过滤：去除低质量或不符合标准的细胞和基因。\n归一化：调整不同细胞的测序深度，使数据可比。\n缩放：对数据进行标准化处理，以便后续分析。\n降维：通过主成分分析（PCA）等方法减少数据维度，便于可视化和聚类。\n聚类：将具有相似转录组特征的细胞分组。\n可视化：生成如t-SNE、UMAP等可视化图表，直观展示细胞群体的分布和差异。\n\n\n\n\n\n技术局限性\n\n低覆盖度与高噪音：\n\n单细胞测序因扩增偏差和随机性，导致基因覆盖度低（仅检测部分基因），数据中存在噪音。\n\n细胞损失与偏差：\n\n分离过程中细胞丢失（捕获效率通常&lt;70%），且不同细胞类型RNA含量差异可能导致信息低估。\n\n数据处理复杂：\n\n需要复杂的生物信息学工具（如归一化、降维、聚类算法），对计算资源要求高。\n\n成本较高：\n\n相比传统测序，单细胞测序成本显著增加（如10x Genomics单细胞转录组测序成本约为传统测序的10倍）。\n\n数据解读困难：\n\n噪音和生物学意义需结合实验验证（如qPCR、FISH）进一步确认。\n\n\n\n\n\n单细胞测序技术在重症医学领域的应用\n\n1. 重症感染性疾病（如脓毒症、结核性脑膜炎）\n\n免疫图谱解析：\n通过单细胞测序（如scRNA-seq）可揭示重症感染患者体内免疫细胞（如巨噬细胞、T细胞、NK细胞）的异质性及功能状态。例如，结核性脑膜炎（TBM）研究中发现，脑脊液（CSF）中富集的微胶质样巨噬细胞（高表达TLR2/4/7和补体成分）及GZMK+CD8+效应记忆T细胞通过干扰素信号通路参与炎症反应，为靶向治疗提供了新靶点。\n病原体-宿主互作：\n单细胞技术可追踪病原体感染后宿主细胞的动态响应。例如，流感病毒研究中，单细胞测序揭示了呼吸道上皮细胞中病毒受体表达差异及免疫细胞浸润模式，为抗病毒药物筛选提供依据。\n\n\n\n2. 多器官功能障碍综合征（MODS）\n\n器官特异性细胞应激：\n在急性呼吸窘迫综合征（ARDS）或急性肾损伤（AKI）中，单细胞测序可识别受损组织中特定细胞亚群（如肺泡上皮细胞、肾小管上皮细胞）的基因表达异常。例如，Stereo-cell技术通过空间转录组分析，可定位肺部组织中炎症因子高表达区域，揭示细胞间通讯紊乱机制。\n微环境动态监测：\n结合多模态整合（转录组+蛋白组+空间定位），Stereo-cell技术可实时捕捉器官微环境中细胞状态变化（如凋亡、代谢重编程），为早期干预提供生物标志物。\n\n\n\n3. 免疫调节失衡（如脓毒症、自身免疫性重症）\n\n免疫细胞功能失调：\n脓毒症患者中，单细胞测序可发现单核/巨噬细胞向M2型极化（促炎到抗炎表型转换）及调节性T细胞（Treg）功能耗竭，揭示免疫抑制状态的分子机制。\n新型生物标志物筛选：\n通过分析重症患者外周血单细胞图谱，可识别与预后相关的特异性标志物（如CD70+白血病干细胞在AML治疗中的耐药性标志物），指导个体化治疗。\n\n\n\n4. 重症监护中的早期预警与分型\n\n动态监测疾病进展：\n单细胞测序可纵向追踪重症患者（如ICU危重病例）的细胞状态变化。例如，通过分析连续血样中的免疫细胞亚群比例及基因表达，预测器官衰竭风险或感染复发。\n精准分型与治疗选择：\n在重症肌无力或系统性红斑狼疮等疾病中，单细胞技术可识别不同免疫表型（如Th17/Treg失衡），辅助制定靶向治疗方案（如IL-6或B细胞抑制剂）。\n\n\n\n\n\n单细胞测序技术在重症医学领域的技术优势\n\n高分辨率解析细胞异质性：\n传统方法掩盖的稀有细胞亚群（如0.05%的耐药干细胞）可通过单细胞测序精准识别。\n动态功能状态分析：\n技术如Stereo-cell支持原位动态测序，实时捕捉细胞代谢、信号通路激活状态（如炎症因子释放、线粒体功能障碍）。\n空间信息整合：\n通过DNA纳米球芯片（Stereo-cell）实现空间转录组定位，解析器官内细胞的空间分布及邻近细胞间的相互作用（如肿瘤微环境中的免疫排斥区域）。\n多组学整合：\n联合转录组、表观组及蛋白组数据，揭示重症疾病中复杂的调控网络（如表观遗传修饰驱动的基因沉默）。\n\n\n\n\n重症医学领域的典型案例\n\n脓毒症免疫失衡研究：\n利用scRNA-seq发现脓毒症患者中单核细胞（CD14+）向M2型极化（高表达CD163、CD206），伴随T细胞耗竭（PD-1+、TIM-3+），提示免疫检查点抑制剂可能逆转免疫抑制状态。\nARDS肺泡上皮修复：\n单细胞测序揭示ARDS患者肺泡Ⅱ型上皮细胞（AT2）中SFTPC突变及代谢重编程（糖酵解增强），为促进肺修复的代谢干预提供靶点。\n重症新冠患者的免疫特征：\n研究显示新冠重症患者中单核细胞衍生的炎症性巨噬细胞（CD16+ CD14+）及组织驻留记忆T细胞（TRM）过度激活，导致细胞因子风暴，指导抗IL-6或JAK抑制剂的使用。"
  },
  {
    "objectID": "rpkg/bayesynergy/index.html",
    "href": "rpkg/bayesynergy/index.html",
    "title": "bayesynergy",
    "section": "",
    "text": "An R package for Bayesian semi-parametric modelling of in-vitro drug combination experiments\nGitHub Link"
  },
  {
    "objectID": "rpkg/csalert/index.html",
    "href": "rpkg/csalert/index.html",
    "title": "csalert",
    "section": "",
    "text": "https://github.com/csids/csalert"
  },
  {
    "objectID": "rpkg/csmaps/index.html",
    "href": "rpkg/csmaps/index.html",
    "title": "csmaps",
    "section": "",
    "text": "https://github.com/csids/csmaps"
  },
  {
    "objectID": "rpkg/ggehr/index.html",
    "href": "rpkg/ggehr/index.html",
    "title": "ggehr",
    "section": "",
    "text": "ggehr (read: gg E-H-R) stands for ggplot2 extension for EHR data, which provides a set of tools to facilitate EHR (Electronic Health Records) visualization.\nggehr package helps you make visualize EHR data, so that you can\n\nhave an overview of the mixed type information related to a patient;\nvisually identify the errors in data recording.\n\nLearn more about ggehr"
  },
  {
    "objectID": "rpkg/mortanor/index.html",
    "href": "rpkg/mortanor/index.html",
    "title": "mortanor",
    "section": "",
    "text": "https://github.com/csids/mortanor"
  },
  {
    "objectID": "rpkg/nowcast/index.html",
    "href": "rpkg/nowcast/index.html",
    "title": "nowcast",
    "section": "",
    "text": "https://github.com/csids/nowcast"
  },
  {
    "objectID": "rpkg/rpkg.html",
    "href": "rpkg/rpkg.html",
    "title": "R packages",
    "section": "",
    "text": "ggehr\n\n\nggplot2 extension to EHR data\n\n\n\n\n\n\n\n\n\n\n\n\nqtwAcademic\n\n\nQuarto Website Templates for Academics\n\n\n\n\n\nNo matching items\n\n\nPublic health\n\n\n\nPackage\nDescription\n\n\n\n\nnoreden\nTools to facilitate nutrition researcher for sustainable diet discovery\n\n\nmedicode\nMetadata for medical classification and clinical coding\n\n\ncsdata\nPre-formatted structured data for Norway\n\n\ncsmaps\nPre-formatted map data for Norway"
  },
  {
    "objectID": "talks/community_20240921_quartofriends/index.html",
    "href": "talks/community_20240921_quartofriends/index.html",
    "title": "Use Quarto, Make Friends",
    "section": "",
    "text": "It has been two years since Quarto became the most popular reproducible publication tool in data science and R community. However Quarto is so much more than just a publication tool! I started using it since late 2022, and it has helped me become more organized, productive and connected with people in the data science community.\nIn this talk I will not focus on the technical aspects on ‘how’ to use this tool. In the first part of the talk, I would like to report the latest news and trends seen in the useR conference and Posit conf, the two biggest global R events. In the second part, I will share my own experience in using Quarto for my career: from learning new skills, collaborating with co-workers, teaching university courses to networking and building a community (CAMIS collaboration). It is a powerful tool to share your work, and make new connections - both for work and for fun! I hope this talk will provide you with some new ideas on how to use this fantastic technology to fulfill your goals."
  },
  {
    "objectID": "talks/ehr_20210218_biday/index.html",
    "href": "talks/ehr_20210218_biday/index.html",
    "title": "Network Analysis of Hospital EHR data",
    "section": "",
    "text": "Since this post doesn’t specify an explicit image, the first image in the post will be used in the listing page of posts."
  },
  {
    "objectID": "talks/ehr_20240918_betterehr/index.html",
    "href": "talks/ehr_20240918_betterehr/index.html",
    "title": "One step closer to better Electronic Health Records data",
    "section": "",
    "text": "Real-World Data (RWD) like Electronic Health Records (EHR) is crucial for understanding drug usage and various treatments and generating Real-World Evidence (RWE). Risk prediction has been a major application where EHR is used, and there is now a shift towards causal inference, which requires data of even higher quality. Patients undergo treatments (drugs, procedures) at various times during their hospital stays, yet the data being recorded are messy and error-prone for various reasons. Analysts spend significant amount of time to sit together with clinicians to identify and understand abnormal records, and unfortunately this process is challenging to automate.\nThis talk will use an example on antibiotics prescription and use at a Nordic hospital to illustrate how some EHR systems can improve for better clinical decision-making and better data for research. I will also introduce a pilot R package (ggehr) that facilitates visual exploration of EHR data, and how it can help reconstruct patient journeys and enable analysts to perform effective quality control."
  },
  {
    "objectID": "talks/ph_20230330_sp/index.html",
    "href": "talks/ph_20230330_sp/index.html",
    "title": "Public health surveillance and reporting",
    "section": "",
    "text": "Time and place: Mar. 30, 2023 12:00 PM–1:00 PM\nHybrid: Georg Sverdrups hus and Zoom\nEvent page"
  },
  {
    "objectID": "talks/ph_20230330_sp/index.html#about-the-topic",
    "href": "talks/ph_20230330_sp/index.html#about-the-topic",
    "title": "Public health surveillance and reporting",
    "section": "About the topic",
    "text": "About the topic\nSituational awareness is key to fast response during a public health emergency, such as COVID-19 pandemic. However, making disease surveillance reports that cover different geographical units for various metrics and data registries is both resource intensive and time consuming. Open source tools such as R packages, GitHub and Airflow can make this process automatic, reproducible and scalable.\nEvery day during the pandemic, Sykdomspulsen team at the Norwegian Institute of Public Health (FHI/NIPH) fetched data from more than 15 data sources, cleaned, censored datasets and carried out a wide range of statistical analyses. Over 1000 situational reports containing automated graphs and tables were produced before breakfast time.\nGrab you matpakke and join us for a presentation from Chi Zhang about how Sykdomspulsen team used and developed open source software to make public health surveillance and reporting more efficient, followed up by a discussion on the benefits and concerns of making these data public. We will end with an open Q&A session as usual!"
  },
  {
    "objectID": "talks/rstats_20230721_teaching/index.html",
    "href": "talks/rstats_20230721_teaching/index.html",
    "title": "Transforming medical statistics classroom with R and Quarto",
    "section": "",
    "text": "Time and place: July 21, 2023 10AM. Roche office, Basel, Switzerland\nSlides for this talk can be accessed here."
  },
  {
    "objectID": "talks/rstats_20230721_teaching/index.html#about-the-topic",
    "href": "talks/rstats_20230721_teaching/index.html#about-the-topic",
    "title": "Transforming medical statistics classroom with R and Quarto",
    "section": "About the topic",
    "text": "About the topic\nThe 8 day introductory statistics course (MF9130) at the Faculty of Medicine, University of Oslo is designed for PhD students in medicine, biology, psychology and other health related fields. Similar to other conventional teaching methods, the course has been focusing largely on theory and hand calculation. The software has been Stata and SPSS, and data analysis was mostly left for the students to figure out on their own.\nThis year, we made an attempt to transform the course with R, and aimed to teach more practical data analysis skills. We added one session per day where the instructor guide students on R and project management, importing data , basic manipulation and statistical methods. The IT skills of the students vary greatly, and therefore we used the ‘sticky notes’ help system borrowed from the Carpentries to make sure everyone could get help in the first days. We have created a course website using Quarto, where all the material and R exercises (with rendered solution) are available for self-study. We have witnessed amazing progress - by the end of the first week, students with the least computer / data skills were able to work on dataframes, make basic plots and do a chi-squared test. This helps build students confidence in data and statistics, and as a result, they can start to work on their own datasets using the skills immediately."
  },
  {
    "objectID": "talks/talks.html",
    "href": "talks/talks.html",
    "title": "Talks",
    "section": "",
    "text": "There is not any talk scheduled."
  },
  {
    "objectID": "talks/talks.html#upcoming",
    "href": "talks/talks.html#upcoming",
    "title": "Talks",
    "section": "",
    "text": "There is not any talk scheduled."
  },
  {
    "objectID": "talks/talks.html#selected-previous-talks",
    "href": "talks/talks.html#selected-previous-talks",
    "title": "Talks",
    "section": "Selected previous talks",
    "text": "Selected previous talks\n\n\n   \n    \n    \n      Order By\n      Default\n      \n        Date - Oldest\n      \n      \n        Date - Newest\n      \n      \n        Title\n      \n    \n  \n    \n      \n      \n    \n\n\n\n\n\n\nTitle\n\n\n\nDescription\n\n\n\nDate\n\n\n\n\n\n\n\n\nUse Quarto, Make Friends\n\n\nKolkata UseR meetup\n\n\n2024-09-21\n\n\n\n\n\n\nOne step closer to better Electronic Health Records data\n\n\nPHUSE Single Day Event Basel\n\n\n2024-09-18\n\n\n\n\n\n\nCAMIS: An Open-Source, Community endeavour for Comparing Analysis Method Implementations\n\n\nUseR! 2024 Salzburg\n\n\n2024-07-10\n\n\n\n\n\n\nA one year recap on teaching statistcis to medical students: how can R and Quarto help?\n\n\nR/Medicine 2024 - Online\n\n\n2024-06-13\n\n\n\n\n\n\nTransforming medical statistics classroom with R and Quarto\n\n\nBasel R meeting\n\n\n2023-07-21\n\n\n\n\n\n\nSykdomspulsen: An automated public health surveillance platform\n\n\nOslo UseR meetup \n\n\n2022-06-16\n\n\n\n\n\n\nNo matching items"
  }
]